{"ticker": {"uuid": "5cce6a56-c9cf-41bc-90a0-d4805a73391f", "symbol": "TVTX", "name": "Travere Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "charts": {"tiers": [{"count": 21, "label": "Direct company coverage"}, {"count": 0, "label": "Industry context"}, {"count": 0, "label": "Sector context"}], "events": [{"count": 12, "label": "Market update"}, {"count": 6, "label": "Earnings"}, {"count": 2, "label": "Analyst action"}, {"count": 1, "label": "Guidance"}], "sources": [{"label": "Investing.com", "count": 5}, {"label": "BioSpace", "count": 3}, {"label": "Stocktwits", "count": 2}, {"label": "finance.yahoo.com", "count": 1}, {"label": "Simply Wall Street", "count": 1}, {"label": "Contract Pharma", "count": 1}, {"label": "Market source", "count": 1}, {"label": "MT Newswires", "count": 1}]}, "insights": [{"text": "Early balanced news score", "tone": "neutral", "label": "Weighted tone", "value": "49/100"}, {"text": "4.12 effective stories after overlap and weighting.", "tone": "neutral", "label": "Evidence confidence", "value": "30/100"}, {"text": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "tone": "neutral", "label": "Market reaction", "value": "Early company-news score"}, {"text": "80/100 evidence concentration around this catalyst.", "tone": "neutral", "label": "Primary event", "value": "Market update"}, {"text": "95% of weighted evidence is company-specific.", "tone": "positive", "label": "Company focus", "value": "21"}, {"text": "lower dispersion means the independent stories agree more closely.", "tone": "positive", "label": "Evidence agreement", "value": "9/100"}, {"text": "-5.2% over one week, -4.5% over four weeks, trend active, and materially above fair value.", "tone": "positive", "label": "Trend context", "value": "Trend active"}, {"text": "Travere receives patent allowance for FILSPARI use in FSGS", "tone": "neutral", "label": "Latest direct headline", "value": "Neutral"}], "classifier": {"events": [{"count": 12, "event": "general", "label": "Market update", "weight": 7.59}, {"count": 6, "event": "earnings", "label": "Earnings", "weight": 4.21}, {"count": 2, "event": "analyst", "label": "Analyst action", "weight": 1.2}, {"count": 1, "event": "guidance", "label": "Guidance", "weight": 0.6}], "pipeline": {"status": "partial", "providers_attempted": 4, "providers_with_results": 3, "raw_articles": 80, "unique_stories": 51, "duplicates_removed": 29, "relevant_stories": 21, "matched_archive_stories": 43, "current_evidence": 5, "direct_evidence": 21, "archive_articles": 4, "durable_story_count": 17, "durable_evidence_used": true, "durable_collected_at": "2026-09-23T16:36:16.108943+00:00"}, "confidence": 80, "primary_event": "general", "primary_label": "Market update", "negative_events": 3, "positive_events": 2}, "updated_at": "2026-09-25T02:12:50.233750+00:00", "total_unique": 21, "total_fetched": 21, "interpretation": {"tone": "neutral", "label": "Early company-news score", "risks": [], "badges": ["Provisional evidence"], "summary": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "confidence": 30, "event_label": "Market update", "opportunities": [], "classification": "provisional", "sentiment_word": "balanced"}, "market_context": {"trend_tone": "positive", "latest_week": "2026-09-18", "trend_label": "Trend active", "latest_close": 62.76, "trend_signal": "1", "one_week_move": -5.2, "reaction_tone": "negative", "fair_value_gap": 179.8, "four_week_move": -4.5, "reaction_label": "Price reacting lower", "fair_value_tone": "negative", "market_dynamics": 0.516686, "market_sentence": "-5.2% over one week, -4.5% over four weeks, trend active, and materially above fair value.", "fair_value_label": "Materially above fair value", "twelve_week_move": 6.6, "relative_strength": 39.879824, "has_market_context": true, "expectation_direction": "positive", "expectation_probability": 58.2195, "market_dynamics_buy_signal": false}, "total_relevant": 21, "pipeline_health": {"status": "partial", "providers_attempted": 4, "providers_with_results": 3, "raw_articles": 80, "unique_stories": 51, "duplicates_removed": 29, "relevant_stories": 21, "matched_archive_stories": 43, "current_evidence": 5, "direct_evidence": 21, "archive_articles": 4, "durable_story_count": 21, "durable_evidence_used": true, "durable_collected_at": "2026-09-25T02:12:50.233750+00:00"}, "sentiment_summary": {"tone": "neutral", "label": "Early balanced news score", "score": 49, "total": 21, "neutral": 16, "negative": 3, "positive": 2, "raw_score": 45, "confidence": 30, "dispersion": 9, "story_count": 21, "window_days": 30, "direct_share": 95, "source_count": 4, "score_version": "evidence-v10", "evidence_count": 5, "evidence_status": "provisional", "information_mass": 0.384, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-09-23T11:51:32+00:00", "direct_story_count": 21, "effective_articles": 4.12, "sector_story_count": 0, "direct_source_count": 4, "industry_story_count": 0, "source_concentration": 0.2581, "directional_story_count": 5}, "articles": [{"url": "https://www.investing.com/news/company-news/travere-receives-patent-allowance-for-filspari-use-in-fsgs-93CH-4912662", "tier": "direct", "title": "Travere receives patent allowance for FILSPARI use in FSGS", "topics": ["Life Sciences"], "summary": "Travere Therapeutics Inc. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering certain methods of using its drug FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS). This patent is expected to provide U.S. coverage for FILSPARI in FSGS until October 2037. The company plans to list the patent in the FDA's Orange Book, further securing its intellectual property for the rare disease treatment.", "age_days": 1.6, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.investing.com/news/company-news/travere-receives-patent-allowance-for-filspari-use-in-fsgs-93CH-4912662", "source_name": "Investing.com", "published_at": "2026-09-23T11:51:32", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 57.5, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.049012, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "23 Sep 2026 11:51", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.biospace.com/press-releases/travere-therapeutics-receives-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-u-s-patent-application-directed-to-certain-methods-of-using-filspari-sparsentan-in-focal-segmental-glomerulosclerosis", "tier": "direct", "title": "Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI\u00ae (sparsentan) in Focal Segmental Glomerulosclerosis", "topics": ["Life Sciences"], "summary": "Travere Therapeutics announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application covering methods of using FILSPARI\u00ae (sparsentan) in focal segmental glomerulosclerosis (FSGS). This patent is expected to provide U.S. coverage until October 2037 and will be listed in the FDA's \"Orange Book.\" The company also recently received a separate U.S. patent for sparsentan's use in IgA nephropathy.", "age_days": 1.6, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.biospace.com/press-releases/travere-therapeutics-receives-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-u-s-patent-application-directed-to-certain-methods-of-using-filspari-sparsentan-in-focal-segmental-glomerulosclerosis", "source_name": "BioSpace", "published_at": "2026-09-23T11:51:32", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 57.5, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.035863, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "23 Sep 2026 11:51", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPNHo3bm9oV0hvLUxyLVhUaEJidkJacl8zblF6Q2dReERaWkdoM2tmeWFSajZ5dmdCa2lyNkVEcHBmX1RwSDlNUVJNTng3bTNJVUpjSENHYXNHcWxrM2VCOVlRMHhwakticE5Yb1ZUQWlPRjFXQlJNd1dHYzBCNDlpNmRvS2xZdmVFMWZSS1BPYXFQZXBrNWpMdlRhaw?oc=5", "tier": "direct", "title": "Travere Therapeutics (TVTX) Sets CEO Handover For December 2026", "topics": [], "summary": "", "age_days": 2.0, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "aggregator", "source_link": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPNHo3bm9oV0hvLUxyLVhUaEJidkJacl8zblF6Q2dReERaWkdoM2tmeWFSajZ5dmdCa2lyNkVEcHBmX1RwSDlNUVJNTng3bTNJVUpjSENHYXNHcWxrM2VCOVlRMHhwakticE5Yb1ZUQWlPRjFXQlJNd1dHYzBCNDlpNmRvS2xZdmVFMWZSS1BPYXFQZXBrNWpMdlRhaw?oc=5", "source_name": "finance.yahoo.com", "published_at": "2026-09-23T01:13:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 49.3, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.02416, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "23 Sep 2026 01:13", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/why-everyone-is-watching-travere-therapeutics-tvtx-today-1", "tier": "direct", "title": "Why Everyone Is Watching Travere Therapeutics (TVTX) Today", "topics": ["Life Sciences", "Financial Markets", "Finance"], "summary": "Travere Therapeutics (TVTX) is experiencing investor focus due to an upcoming leadership change, with CEO Eric Dube stepping down on December 1, 2026. The stock currently trades at a significant discount to analyst targets and fair value estimates, driven by the potential expansion of its drug Filspari's label to treat FSGS. While the company shows strong long-term shareholder returns, its future relies heavily on the success of Filspari, posing both opportunity and execution risks.", "age_days": 2.2, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/why-everyone-is-watching-travere-therapeutics-tvtx-today-1", "source_name": "Simply Wall Street", "published_at": "2026-09-22T20:21:59", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "freshness_pct": 46.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.03233, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "22 Sep 2026 20:21", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.contractpharma.com/breaking-news/travere-therapeutics-names-bradley-campbell-ceo", "tier": "direct", "title": "Travere Therapeutics Names Bradley Campbell CEO", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "Travere Therapeutics announced that Bradley L. Campbell, former president and CEO of Amicus Therapeutics, will succeed Eric Dube as president and CEO, effective December 1, 2026. Dube, who led Travere's evolution into a rare disease company and achieved significant regulatory approvals, will remain an executive advisor until February 15, 2027, to ensure a smooth transition. Campbell brings over 25 years of biopharmaceutical experience, with a strong focus on rare diseases, and aims to build on Travere's momentum and expand its reach to more patients.", "age_days": 2.4, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.contractpharma.com/breaking-news/travere-therapeutics-names-bradley-campbell-ceo", "source_name": "Contract Pharma", "published_at": "2026-09-22T16:51:33", "tone_signals": ["Regulatory Approval"], "company_focus": 0.78, "freshness_pct": 71.8, "sentiment_pct": 58, "evidence_basis": "archived_article", "evidence_share": 23.8, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.091446, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 78, "evidence_strength": 47, "published_display": "22 Sep 2026 16:51", "direction_included": true, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "23.8"}, {"url": "https://sg.finance.yahoo.com/news/travere-therapeutics-tvtx-stock-may-141323925.html", "tier": "direct", "title": "Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today", "topics": ["Biotech", "Earnings", "Financial Markets", "Life Sciences", "Price To Sales", "Revenue"], "summary": "Travere Therapeutics (TVTX) stock has seen significant price gains, leading to questions about its current valuation relative to revenue. While the stock's P/S ratio is lower than the biotech industry average, a \"Fair Ratio\" model suggests it might be overvalued based on growth outlook, margins, size, and risk. Analysts present both bull and bear cases, focusing on FILSPARI's potential and reliance on the product, respectively.", "age_days": 2.5, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "aggregator", "source_link": "https://sg.finance.yahoo.com/news/travere-therapeutics-tvtx-stock-may-141323925.html", "source_name": "Market source", "published_at": "2026-09-22T14:13:00", "tone_signals": ["Deteriorating financial comparison", "Negative valuation view"], "company_focus": 1.0, "freshness_pct": 70.7, "sentiment_pct": 41, "evidence_basis": "archived_article", "evidence_share": 32.6, "score_included": true, "duplicate_count": 3, "evidence_weight": 0.125352, "influence_label": "Medium", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 51, "published_display": "22 Sep 2026 14:13", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "32.6"}, {"url": "https://www.biospace.com/press-releases/travere-therapeutics-announces-planned-chief-executive-officer-transition", "tier": "direct", "title": "Travere Therapeutics Announces Planned Chief Executive Officer Transition", "topics": ["Biotech", "Leadership Change", "Life Sciences", "Rare Diseases"], "summary": "Travere Therapeutics announced that its President and CEO, Eric Dube, Ph.D., will step down in December 2026 due to personal health and family reasons after eight years of leadership. Bradley L. Campbell, former president and CEO of Amicus Therapeutics, will succeed him, effective December 1, 2026. Dube will remain as an executive advisor until February 2027 to ensure a smooth transition, as Campbell aims to build on Travere's momentum in rare disease therapies.", "age_days": 3.0, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.biospace.com/press-releases/travere-therapeutics-announces-planned-chief-executive-officer-transition", "source_name": "BioSpace", "published_at": "2026-09-22T03:23:53", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 36.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.017206, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "22 Sep 2026 03:23", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.investing.com/news/stock-market-news/travere-therapeutics-stock-falls-amid-ceo-transition-news-93CH-4909642", "tier": "direct", "title": "Travere Therapeutics stock falls amid CEO transition news", "topics": ["Life Sciences"], "summary": "Travere Therapeutics Inc. (NASDAQ:TVTX) shares fell in after-hours trading following the announcement of CEO Eric Dube's departure in December 2026 due to health and family reasons. Bradley L. Campbell, former president and CEO of Amicus Therapeutics, will succeed Dube, bringing over 25 years of biopharmaceutical experience to the role. Dube, who led the company through significant regulatory approvals, will remain as an executive advisor during the transition.", "age_days": 3.0, "is_stale": false, "sentiment": "negative", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.investing.com/news/stock-market-news/travere-therapeutics-stock-falls-amid-ceo-transition-news-93CH-4909642", "source_name": "Investing.com", "published_at": "2026-09-22T03:23:53", "tone_signals": ["Negative market reaction"], "company_focus": 1.0, "freshness_pct": 36.0, "sentiment_pct": 38, "evidence_basis": "archived_article", "evidence_share": 18.1, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.069691, "influence_label": "Medium", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 45, "published_display": "22 Sep 2026 03:23", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "18.1"}, {"url": "https://finance.yahoo.com/healthcare/articles/travere-therapeutics-president-ceo-eric-204224859.html", "tier": "direct", "title": "Travere Therapeutics President and CEO Eric Dube Plans to Step Down", "topics": ["Life Sciences"], "summary": "Travere Therapeutics (TVTX) announced that its President and CEO, Eric Dube, plans to step down. The information was released late Monday by MT Newswires. Further details regarding Dube's departure are available to premium subscribers.", "age_days": 3.2, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/travere-therapeutics-president-ceo-eric-204224859.html", "source_name": "MT Newswires", "published_at": "2026-09-21T20:42:24+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 32.7, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.020375, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "21 Sep 2026 20:42", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOX29QeTAzZFFMZEw3U1MxZjdfU2NMNmJHSVBvTGNFRHVwVzhnZzdHUnFhazMtcHhWNUFHeUVTZE1xZWNsOHg3dnRmVmVQbWRYTEdjTndEUk11a2c5TzNkUWpidndWMWpueXJZdlp0Ml9sRHNxU2VkMzRfU01TWlBlbVJaR1JBc0E1eDBFaFcyLXZGQUNJbTVzZXJYd3hXZDd2SDRSN3ozZm1rZkw4cF9sWnJReS1HNXNiWjVMNkxLRVNTVjNGUmZxTHVVaXl2MHRHOFlZbTJGV1c?oc=5", "tier": "direct", "title": "Travere Therapeutics (NASDAQ:TVTX) Passes Minervini Trend Template With High-Growth Momentum", "topics": [], "summary": "", "age_days": 3.6, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOX29QeTAzZFFMZEw3U1MxZjdfU2NMNmJHSVBvTGNFRHVwVzhnZzdHUnFhazMtcHhWNUFHeUVTZE1xZWNsOHg3dnRmVmVQbWRYTEdjTndEUk11a2c5TzNkUWpidndWMWpueXJZdlp0Ml9sRHNxU2VkMzRfU01TWlBlbVJaR1JBc0E1eDBFaFcyLXZGQUNJbTVzZXJYd3hXZDd2SDRSN3ozZm1rZkw4cF9sWnJReS1HNXNiWjVMNkxLRVNTVjNGUmZxTHVVaXl2MHRHOFlZbTJGV1c?oc=5", "source_name": "ChartMill", "published_at": "2026-09-21T12:41:07+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 29.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.015552, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "21 Sep 2026 12:41", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.investing.com/news/insider-trading-news/travere-therapeutics-evp-peter-heerma-sells-178m-in-company-stock-93CH-4906654", "tier": "direct", "title": "Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Peter Heerma, EVP and CCO at Travere Therapeutics (NASDAQ:TVTX), sold approximately $17.86 million worth of company stock through a pre-arranged trading plan between September 15-17, 2026. Concurrently, he acquired about $4.05 million in common stock by exercising employee options. These transactions occurred as TVTX shares approached a 52-week high, with the stock deemed overvalued by InvestingPro analysis, despite the company reporting strong Q2 2026 revenue driven by its kidney drug, FILSPARI.", "age_days": 6.4, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.investing.com/news/insider-trading-news/travere-therapeutics-evp-peter-heerma-sells-178m-in-company-stock-93CH-4906654", "source_name": "Investing.com", "published_at": "2026-09-18T15:53:12", "tone_signals": ["Operating growth", "Negative valuation view"], "company_focus": 1.0, "freshness_pct": 41.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.077205, "influence_label": "None", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 15:53", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.marketscreener.com/news/travere-therapeutics-insider-sold-shares-worth-25-390-729-according-to-a-recent-sec-filing-ce785adad88af424", "tier": "direct", "title": "Travere Therapeutics Insider Sold Shares Worth $25,390,729, According to a Recent SEC Filing", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "An insider at Travere Therapeutics sold shares valued at $25,390,729, as reported in a recent SEC filing. The article, published on September 18, 2026, by MT Newswires, provides this specific transaction detail among other insider sales for the company. Travere Therapeutics is a biopharmaceutical firm focused on rare kidney and metabolic diseases.", "age_days": 6.4, "is_stale": false, "sentiment": "negative", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketscreener.com/news/travere-therapeutics-insider-sold-shares-worth-25-390-729-according-to-a-recent-sec-filing-ce785adad88af424", "source_name": "www.marketscreener.com", "published_at": "2026-09-18T15:53:12", "tone_signals": ["Institutional or insider selling"], "company_focus": 1.0, "freshness_pct": 41.0, "sentiment_pct": 40, "evidence_basis": "archived_article", "evidence_share": 21.1, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.08119, "influence_label": "Medium", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 46, "published_display": "18 Sep 2026 15:53", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "21.1"}, {"url": "https://www.biospace.com/press-releases/travere-therapeutics-to-present-at-the-stifel-2026-virtual-immunology-and-inflammation-forum", "tier": "direct", "title": "Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum", "topics": ["Biotech", "Finance", "Life Sciences"], "summary": "Travere Therapeutics, Inc. (Nasdaq: TVTX) announced that its management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET. A live webcast of the presentation will be available on the Investor page of Travere\u2019s website, with a replay accessible for up to 30 days. The company, a biopharmaceutical firm focused on rare diseases, aims to develop and deliver life-changing therapies to patients and caregivers.", "age_days": 6.5, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.biospace.com/press-releases/travere-therapeutics-to-present-at-the-stifel-2026-virtual-immunology-and-inflammation-forum", "source_name": "BioSpace", "published_at": "2026-09-18T15:10:34", "tone_signals": [], "company_focus": 0.78, "freshness_pct": 10.7, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.00437, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 78, "evidence_strength": 0, "published_display": "18 Sep 2026 15:10", "direction_included": false, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNR2J5Q0FmYUM5cmEzLW4xSmh3aFVJckliQjVMZVJITE9XTy1jeC1pSkJyUUpfcWhMSWxsWkxxSy1GOGo0bmUxSmJKcWlpQjBsYXFJM21DZUZ4WWpEZVZ3alhCSEowODVKaHVBWTd0b3R6cldzYVBuQ1M5ZFlWbWlUWVJSM1AtdS1HTEt6bndfc0VDSFc3M1hkWWJQcm9CSVdyMlBfRGpjRWczRW11ckxEWWZqRE0wZXBsUE5Nd2xJSmd2MlFWTW9MSDN6MnFKY2x0ZHJHTVJfZlpuRFcxbE1XOHBJVXFvMXRBZV84?oc=5", "tier": "direct", "title": "TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside", "topics": [], "summary": "", "age_days": 12.3, "is_stale": false, "sentiment": "neutral", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNR2J5Q0FmYUM5cmEzLW4xSmh3aFVJckliQjVMZVJITE9XTy1jeC1pSkJyUUpfcWhMSWxsWkxxSy1GOGo0bmUxSmJKcWlpQjBsYXFJM21DZUZ4WWpEZVZ3alhCSEowODVKaHVBWTd0b3R6cldzYVBuQ1M5ZFlWbWlUWVJSM1AtdS1HTEt6bndfc0VDSFc3M1hkWWJQcm9CSVdyMlBfRGpjRWczRW11ckxEWWZqRE0wZXBsUE5Nd2xJSmd2MlFWTW9MSDN6MnFKY2x0ZHJHTVJfZlpuRFcxbE1XOHBJVXFvMXRBZV84?oc=5", "source_name": "Stocktwits", "published_at": "2026-09-12T19:17:30+00:00", "tone_signals": ["Negative market reaction"], "company_focus": 1.0, "freshness_pct": 5.8, "sentiment_pct": 46, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.006034, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "12 Sep 2026 19:17", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://ca.finance.yahoo.com/news/travere-therapeutics-reports-inducement-grants-210000130.html", "tier": "direct", "title": "Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "topics": ["Biopharmaceuticals", "Equity Grants", "Finance", "Life Sciences", "Nasdaq"], "summary": "Travere Therapeutics announced that its Board of Directors' Compensation Committee granted inducement equity awards to 16 new employees. These grants, totaling 56,220 restricted stock units (RSUs), are an inducement for their employment under Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on continued employment.", "age_days": 13.4, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://ca.finance.yahoo.com/news/travere-therapeutics-reports-inducement-grants-210000130.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-09-11T16:00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 1.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.000595, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Sep 2026 16:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.investing.com/news/company-news/travere-therapeutics-stock-hits-52week-high-at-6825-usd-93CH-4896415", "tier": "direct", "title": "Travere Therapeutics stock hits 52-week high at 68.25 USD", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Travere Therapeutics (TVTX) stock reached a new 52-week high of $68.25, marking a significant 172.32% increase over the past year due to strong investor confidence and 77% revenue growth. The company's kidney drug, FILSPARI, has been a key driver, with second-quarter revenue exceeding forecasts at $169.6 million. Despite appearing overvalued, analysts predict profitability for TVTX this year.", "age_days": 13.7, "is_stale": false, "sentiment": "neutral", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.investing.com/news/company-news/travere-therapeutics-stock-hits-52week-high-at-6825-usd-93CH-4896415", "source_name": "Investing.com", "published_at": "2026-09-11T08:57:54", "tone_signals": ["Operating growth", "Negative valuation view"], "company_focus": 1.0, "freshness_pct": 14.9, "sentiment_pct": 53, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.03202, "influence_label": "None", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Sep 2026 08:57", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.mmm-online.com/news/fda-untitled-letter-travere-therapeutics-kidney-disease-drug-filspari", "tier": "direct", "title": "FDA issues Untitled Letter to Travere Therapeutics over visual aid for kidney disease drug Filspari", "topics": ["Finance", "Life Sciences"], "summary": "The FDA's Office of Prescription Drug Promotion has issued an Untitled Letter to Travere Therapeutics concerning its visual aid for the kidney disease drug, Filspari. The agency claims that several statements in the visual aid, intended for physicians, are misleading as they are not supported by clinical data. The FDA highlighted issues with claims regarding \"kidney preservation,\" \"complete remission of proteinuria,\" and the drug being \"well tolerated,\" demanding a response from Travere Therapeutics within 15 working days.", "age_days": 15.6, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.mmm-online.com/news/fda-untitled-letter-travere-therapeutics-kidney-disease-drug-filspari", "source_name": "Medical Marketing and Media", "published_at": "2026-09-09T11:02:34", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 0.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.000277, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "09 Sep 2026 11:02", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPb0EtcjFYdFRqd1VqXzh0bW56SEtPbk8xajRHbm95SU5SWmx0Zkd3bDFQc2U4a0hxaVVIcWtXbHVEcF9sU2RyWjlRcUhMVGpnbVN2ZHNvN25LM1BvNUN3anVHQVk1RzRlOGYydF9nQkFQcW5hX3pSdkVPR1M0YnBOVQ?oc=5", "tier": "direct", "title": "Travere Therapeutics' Outlook Brightens As Turnaround Looms", "topics": [], "summary": "Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers near a buy zone. Continue Reading", "age_days": 16.8, "is_stale": false, "sentiment": "neutral", "event_type": "guidance", "tier_label": "Direct company coverage", "event_label": "Guidance", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPb0EtcjFYdFRqd1VqXzh0bW56SEtPbk8xajRHbm95SU5SWmx0Zkd3bDFQc2U4a0hxaVVIcWtXbHVEcF9sU2RyWjlRcUhMVGpnbVN2ZHNvN25LM1BvNUN3anVHQVk1RzRlOGYydF9nQkFQcW5hX3pSdkVPR1M0YnBOVQ?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-09-08T07:00:00+00:00", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 18.9, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "evidence_weight": 0.021825, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "08 Sep 2026 07:00", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNR2J5Q0FmYUM5cmEzLW4xSmh3aFVJckliQjVMZVJITE9XTy1jeC1pSkJyUUpfcWhMSWxsWkxxSy1GOGo0bmUxSmJKcWlpQjBsYXFJM21DZUZ4WWpEZVZ3alhCSEowODVKaHVBWTd0b3R6cldzYVBuQ1M5ZFlWbWlUWVJSM1AtdS1HTEt6bndfc0VDSFc3M1hkWWJQcm9CSVdyMlBfRGpjRWczRW11ckxEWWZqRE0wZXBsUE5Nd2xJSmd2MlFWTW9MSDN6MnFKY2x0ZHJHTVJfZlpuRFcxbE1XOHBJVXFvMXRBZV84?oc=5", "tier": "direct", "title": "TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside", "topics": [], "summary": "", "age_days": 19.3, "is_stale": false, "sentiment": "neutral", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNR2J5Q0FmYUM5cmEzLW4xSmh3aFVJckliQjVMZVJITE9XTy1jeC1pSkJyUUpfcWhMSWxsWkxxSy1GOGo0bmUxSmJKcWlpQjBsYXFJM21DZUZ4WWpEZVZ3alhCSEowODVKaHVBWTd0b3R6cldzYVBuQ1M5ZFlWbWlUWVJSM1AtdS1HTEt6bndfc0VDSFc3M1hkWWJQcm9CSVdyMlBfRGpjRWczRW11ckxEWWZqRE0wZXBsUE5Nd2xJSmd2MlFWTW9MSDN6MnFKY2x0ZHJHTVJfZlpuRFcxbE1XOHBJVXFvMXRBZV84?oc=5", "source_name": "Stocktwits", "published_at": "2026-09-05T18:53:23+00:00", "tone_signals": ["Negative market reaction"], "company_focus": 1.0, "freshness_pct": 1.2, "sentiment_pct": 46, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.001193, "influence_label": "None", "event_confidence": 53, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "05 Sep 2026 18:53", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, {"url": "https://www.investing.com/news/company-news/travere-therapeutics-stock-hits-52week-high-at-6797-usd-93CH-4888110", "tier": "direct", "title": "Travere Therapeutics stock hits 52-week high at 67.97 USD", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Travere Therapeutics (TVTX) stock recently hit a 52-week high of $68.03, reflecting a 243% 1-year return, driven by strong investor confidence and impressive Q2 revenue of $169.6 million. This performance was significantly boosted by high demand for its kidney drug, FILSPARI, leading Stifel to raise its price target to $62. The stock is currently trading above its Fair Value according to InvestingPro data, signaling strong future growth expectations.", "age_days": 20.9, "is_stale": false, "sentiment": "positive", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.investing.com/news/company-news/travere-therapeutics-stock-hits-52week-high-at-6797-usd-93CH-4888110", "source_name": "Investing.com", "published_at": "2026-09-04T04:54:55", "tone_signals": ["Analyst upgrade", "Operating growth"], "company_focus": 1.0, "freshness_pct": 5.5, "sentiment_pct": 63, "evidence_basis": "archived_article", "evidence_share": 4.3, "score_included": true, "duplicate_count": 4, "evidence_weight": 0.016461, "influence_label": "Medium", "event_confidence": 61, "company_focus_pct": 100, "evidence_strength": 40, "published_display": "04 Sep 2026 04:54", "direction_included": true, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "4.3"}, {"url": "https://kalkinemedia.com/us/news/announcements/travere-therapeutics-cfo-christopher-r-cline-executes-642-share-sale-for-tax-withholding-on-rsu-vesting", "tier": "direct", "title": "Travere Therapeutics CFO Christopher R. Cline Executes 642-Share Sale for Tax Withholding on RSU Vesting", "topics": ["Finance", "Life Sciences"], "summary": "Christopher R. Cline, CFO of Travere Therapeutics, sold 642 shares of common stock on September 2, 2026, at $66.37 per share. This transaction was not a discretionary trade but a mandatory \"sell to cover\" to fulfill tax withholding obligations arising from vested restricted stock units. Following the sale, Cline beneficially owns 118,016 shares of the company's common stock.", "age_days": 21.0, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://kalkinemedia.com/us/news/announcements/travere-therapeutics-cfo-christopher-r-cline-executes-642-share-sale-for-tax-withholding-on-rsu-vesting", "source_name": "Kalkine Media", "published_at": "2026-09-04T02:31:14", "tone_signals": ["Institutional or insider selling"], "company_focus": 1.0, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 5.7e-05, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "04 Sep 2026 02:31", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}], "by_tier": {"direct": [{"url": "https://www.investing.com/news/company-news/travere-receives-patent-allowance-for-filspari-use-in-fsgs-93CH-4912662", "tier": "direct", "title": "Travere receives patent allowance for FILSPARI use in FSGS", "topics": ["Life Sciences"], "summary": "Travere Therapeutics Inc. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering certain methods of using its drug FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS). This patent is expected to provide U.S. coverage for FILSPARI in FSGS until October 2037. The company plans to list the patent in the FDA's Orange Book, further securing its intellectual property for the rare disease treatment.", "age_days": 1.6, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "449417367eaca7b8215ff5895d9716925b1a8112e6c6bd9421a5c416a9dcac2b", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.investing.com/news/company-news/travere-receives-patent-allowance-for-filspari-use-in-fsgs-93CH-4912662", "source_name": "Investing.com", "published_at": "2026-09-23T11:51:32", "source_names": ["Investing.com"], "target_scope": "Travere receives patent allowance for FILSPARI use in FSGS Travere Therapeutics Inc.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 57.5, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.049012, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TVTX"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "23 Sep 2026 11:51", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TVTX", "provider_directional_mass": 0.4127}, {"url": "https://www.biospace.com/press-releases/travere-therapeutics-receives-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-u-s-patent-application-directed-to-certain-methods-of-using-filspari-sparsentan-in-focal-segmental-glomerulosclerosis", "tier": "direct", "title": "Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI\u00ae (sparsentan) in Focal Segmental Glomerulosclerosis", "topics": ["Life Sciences"], "summary": "Travere Therapeutics announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application covering methods of using FILSPARI\u00ae (sparsentan) in focal segmental glomerulosclerosis (FSGS). This patent is expected to provide U.S. coverage until October 2037 and will be listed in the FDA's \"Orange Book.\" The company also recently received a separate U.S. patent for sparsentan's use in IgA nephropathy.", "age_days": 1.6, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "6087afb440f671d0bb865aa5319f651fd4a83731bc133aa59defd8122709e185", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.biospace.com/press-releases/travere-therapeutics-receives-notice-of-allowance-from-the-u-s-patent-and-trademark-office-for-u-s-patent-application-directed-to-certain-methods-of-using-filspari-sparsentan-in-focal-segmental-glomerulosclerosis", "source_name": "BioSpace", "published_at": "2026-09-23T11:51:32", "source_names": ["BioSpace"], "target_scope": "Travere Therapeutics Receives Notice of Allowance from the U.S. Travere Therapeutics announced that the U.S.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 57.5, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.035863, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TVTX"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "23 Sep 2026 11:51", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TVTX", "provider_directional_mass": 0.4801}, {"url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPNHo3bm9oV0hvLUxyLVhUaEJidkJacl8zblF6Q2dReERaWkdoM2tmeWFSajZ5dmdCa2lyNkVEcHBmX1RwSDlNUVJNTng3bTNJVUpjSENHYXNHcWxrM2VCOVlRMHhwakticE5Yb1ZUQWlPRjFXQlJNd1dHYzBCNDlpNmRvS2xZdmVFMWZSS1BPYXFQZXBrNWpMdlRhaw?oc=5", "tier": "direct", "title": "Travere Therapeutics (TVTX) Sets CEO Handover For December 2026", "topics": [], "summary": "", "age_days": 2.0, "is_stale": false, "provider": "archive", "providers": ["archive", "google_news"], "sentiment": "neutral", "story_key": "c7b0b7c774b6dd5d3f53adc787292faa249eb2374a56812258f0eb956824a175", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "aggregator", "source_link": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPNHo3bm9oV0hvLUxyLVhUaEJidkJacl8zblF6Q2dReERaWkdoM2tmeWFSajZ5dmdCa2lyNkVEcHBmX1RwSDlNUVJNTng3bTNJVUpjSENHYXNHcWxrM2VCOVlRMHhwakticE5Yb1ZUQWlPRjFXQlJNd1dHYzBCNDlpNmRvS2xZdmVFMWZSS1BPYXFQZXBrNWpMdlRhaw?oc=5", "source_name": "finance.yahoo.com", "published_at": "2026-09-23T01:13:00+00:00", "source_names": ["finance.yahoo.com"], "target_scope": "Travere Therapeutics (TVTX) Sets CEO Handover For December 2026", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 49.3, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.02416, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TVTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "23 Sep 2026 01:13", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TVTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/why-everyone-is-watching-travere-therapeutics-tvtx-today-1", "tier": "direct", "title": "Why Everyone Is Watching Travere Therapeutics (TVTX) Today", "topics": ["Life Sciences", "Financial Markets", "Finance"], "summary": "Travere Therapeutics (TVTX) is experiencing investor focus due to an upcoming leadership change, with CEO Eric Dube stepping down on December 1, 2026. The stock currently trades at a significant discount to analyst targets and fair value estimates, driven by the potential expansion of its drug Filspari's label to treat FSGS. While the company shows strong long-term shareholder returns, its future relies heavily on the success of Filspari, posing both opportunity and execution risks.", "age_days": 2.2, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "7ab898c1ff600c2bab58cbbf3b259fe6e9206949d87447dd5b07a3db128ef71b", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/why-everyone-is-watching-travere-therapeutics-tvtx-today-1", "source_name": "Simply Wall Street", "published_at": "2026-09-22T20:21:59", "source_names": ["Simply Wall Street"], "target_scope": "Why Everyone Is Watching Travere Therapeutics (TVTX) Today Travere Therapeutics (TVTX) is experiencing investor focus due to an upcoming leadership change, with CEO Eric Dube stepping down on December 1, 2026.", "tone_signals": ["Positive financial language"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 46.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.03233, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.451, "provider_symbols": ["TVTX"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "22 Sep 2026 20:21", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TVTX", "provider_directional_mass": 0.334}, {"url": "https://www.contractpharma.com/breaking-news/travere-therapeutics-names-bradley-campbell-ceo", "tier": "direct", "title": "Travere Therapeutics Names Bradley Campbell CEO", "topics": ["Earnings", "Finance", "Financial Markets", "Life Sciences"], "summary": "Travere Therapeutics announced that Bradley L. Campbell, former president and CEO of Amicus Therapeutics, will succeed Eric Dube as president and CEO, effective December 1, 2026. Dube, who led Travere's evolution into a rare disease company and achieved significant regulatory approvals, will remain an executive advisor until February 15, 2027, to ensure a smooth transition. Campbell brings over 25 years of biopharmaceutical experience, with a strong focus on rare diseases, and aims to build on Travere's momentum and expand its reach to more patients.", "age_days": 2.4, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "positive", "story_key": "0255d2d3660f2b3a4d73bc1bef5bca7c722ef02f390457437ecadc5adaf06524", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.contractpharma.com/breaking-news/travere-therapeutics-names-bradley-campbell-ceo", "source_name": "Contract Pharma", "published_at": "2026-09-22T16:51:33", "source_names": ["Contract Pharma"], "target_scope": "Travere Therapeutics Names Bradley Campbell CEO Travere Therapeutics announced that Bradley L. Campbell, former president and CEO of Amicus Therapeutics, will succeed Eric Dube as president and CEO, effective December 1, 2026. Dube, who led Travere's evolution into a rare disease company and achieved significant regulatory approvals, will remain an executive advisor until February 15, 2027, to ensure a smooth transition. Campbell brings over 25 years of biopharmaceutical experience, with a strong focus on rare diseases, and aims to build on Travere's momentum and expand its reach to more patients.", "tone_signals": ["Regulatory Approval"], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 71.8, "sentiment_pct": 58, "evidence_basis": "archived_article", "evidence_share": 23.8, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.091446, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.555, "provider_symbols": ["BMY", "TVTX"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 47, "published_display": "22 Sep 2026 16:51", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "23.8", "target_provider_symbol": "TVTX", "provider_directional_mass": 0.4445}, {"url": "https://sg.finance.yahoo.com/news/travere-therapeutics-tvtx-stock-may-141323925.html", "tier": "direct", "title": "Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today", "topics": ["Biotech", "Earnings", "Financial Markets", "Life Sciences", "Price To Sales", "Revenue"], "summary": "Travere Therapeutics (TVTX) stock has seen significant price gains, leading to questions about its current valuation relative to revenue. While the stock's P/S ratio is lower than the biotech industry average, a \"Fair Ratio\" model suggests it might be overvalued based on growth outlook, margins, size, and risk. Analysts present both bull and bear cases, focusing on FILSPARI's potential and reliance on the product, respectively.", "age_days": 2.5, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "negative", "story_key": "e151fd6ecb2301dc594a3399619d2fab4f7ad3bc3da3df230677cae95c15928c", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "aggregator", "source_link": "https://sg.finance.yahoo.com/news/travere-therapeutics-tvtx-stock-may-141323925.html", "source_name": "Market source", "published_at": "2026-09-22T14:13:00", "source_names": ["Market source"], "target_scope": "Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today Travere Therapeutics (TVTX) stock has seen significant price gains, leading to questions about its current valuation relative to revenue.", "tone_signals": ["Deteriorating financial comparison", "Negative valuation view"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 70.7, "sentiment_pct": 41, "evidence_basis": "archived_article", "evidence_share": 32.6, "score_included": true, "duplicate_count": 3, "durable_archive": false, "evidence_weight": 0.125352, "influence_label": "Medium", "provider_symbol": "TVTX.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.639, "provider_symbols": ["TVTX", "TVTX.ARCHIVE", "TVTX.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 51, "published_display": "22 Sep 2026 14:13", "direction_included": true, "sentiment_conflict": 0.17, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "32.6", "target_provider_symbol": "TVTX", "provider_directional_mass": 0.232}, {"url": "https://www.biospace.com/press-releases/travere-therapeutics-announces-planned-chief-executive-officer-transition", "tier": "direct", "title": "Travere Therapeutics Announces Planned Chief Executive Officer Transition", "topics": ["Biotech", "Leadership Change", "Life Sciences", "Rare Diseases"], "summary": "Travere Therapeutics announced that its President and CEO, Eric Dube, Ph.D., will step down in December 2026 due to personal health and family reasons after eight years of leadership. Bradley L. Campbell, former president and CEO of Amicus Therapeutics, will succeed him, effective December 1, 2026. Dube will remain as an executive advisor until February 2027 to ensure a smooth transition, as Campbell aims to build on Travere's momentum in rare disease therapies.", "age_days": 3.0, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "37ce1caf7c8fe86c5e6aac6f32d25879429e84eecbbad17c0fbd1db5eb1672ce", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.biospace.com/press-releases/travere-therapeutics-announces-planned-chief-executive-officer-transition", "source_name": "BioSpace", "published_at": "2026-09-22T03:23:53", "source_names": ["BioSpace"], "target_scope": "Travere Therapeutics Announces Planned Chief Executive Officer Transition Travere Therapeutics announced that its President and CEO, Eric Dube, Ph.D., will step down in December 2026 due to personal health and family reasons after eight years of leadership. Campbell, former president and CEO of Amicus Therapeutics, will succeed him, effective December 1, 2026. Dube will remain as an executive advisor until February 2027 to ensure a smooth transition, as Campbell aims to build on Travere's momentum in rare disease therapies.", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 36.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.017206, "influence_label": "None", "provider_symbol": "TVTX.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["BMRN", "BMRN.US", "TVTX", "TVTX.ARCHIVE", "TVTX.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "22 Sep 2026 03:23", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TVTX", "provider_directional_mass": 0.2048}, {"url": "https://www.investing.com/news/stock-market-news/travere-therapeutics-stock-falls-amid-ceo-transition-news-93CH-4909642", "tier": "direct", "title": "Travere Therapeutics stock falls amid CEO transition news", "topics": ["Life Sciences"], "summary": "Travere Therapeutics Inc. (NASDAQ:TVTX) shares fell in after-hours trading following the announcement of CEO Eric Dube's departure in December 2026 due to health and family reasons. Bradley L. Campbell, former president and CEO of Amicus Therapeutics, will succeed Dube, bringing over 25 years of biopharmaceutical experience to the role. Dube, who led the company through significant regulatory approvals, will remain as an executive advisor during the transition.", "age_days": 3.0, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "negative", "story_key": "9f632e816614fa61c6dd25f31b922348c2f031ebbea25a93752bd305aee4a896", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.investing.com/news/stock-market-news/travere-therapeutics-stock-falls-amid-ceo-transition-news-93CH-4909642", "source_name": "Investing.com", "published_at": "2026-09-22T03:23:53", "source_names": ["Investing.com"], "target_scope": "Travere Therapeutics stock falls amid CEO transition news Travere Therapeutics Inc. (NASDAQ:TVTX) shares fell in after-hours trading following the announcement of CEO Eric Dube's departure in December 2026 due to health and family reasons. Campbell, former president and CEO of Amicus Therapeutics, will succeed Dube, bringing over 25 years of biopharmaceutical experience to the role.", "tone_signals": ["Negative market reaction"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 36.0, "sentiment_pct": 38, "evidence_basis": "archived_article", "evidence_share": 18.1, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.069691, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.672, "provider_symbols": ["TVTX", "TVTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 45, "published_display": "22 Sep 2026 03:23", "direction_included": true, "sentiment_conflict": 0.401, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "18.1", "target_provider_symbol": "TVTX", "provider_directional_mass": 0.3818}, {"url": "https://finance.yahoo.com/healthcare/articles/travere-therapeutics-president-ceo-eric-204224859.html", "tier": "direct", "title": "Travere Therapeutics President and CEO Eric Dube Plans to Step Down", "topics": ["Life Sciences"], "summary": "Travere Therapeutics (TVTX) announced that its President and CEO, Eric Dube, plans to step down. The information was released late Monday by MT Newswires. Further details regarding Dube's departure are available to premium subscribers.", "age_days": 3.2, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "0f4d655cab6dc4e88376e00e1209e84ea6637c6f8c008cf9dd10c7810a06be06", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://finance.yahoo.com/healthcare/articles/travere-therapeutics-president-ceo-eric-204224859.html", "source_name": "MT Newswires", "published_at": "2026-09-21T20:42:24+00:00", "source_names": ["MT Newswires"], "target_scope": "Travere Therapeutics President and CEO Eric Dube Plans to Step Down Travere Therapeutics (TVTX) announced that its President and CEO, Eric Dube, plans to step down.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 32.7, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.020375, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "yfinance", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TVTX", "TVTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "21 Sep 2026 20:42", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TVTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOX29QeTAzZFFMZEw3U1MxZjdfU2NMNmJHSVBvTGNFRHVwVzhnZzdHUnFhazMtcHhWNUFHeUVTZE1xZWNsOHg3dnRmVmVQbWRYTEdjTndEUk11a2c5TzNkUWpidndWMWpueXJZdlp0Ml9sRHNxU2VkMzRfU01TWlBlbVJaR1JBc0E1eDBFaFcyLXZGQUNJbTVzZXJYd3hXZDd2SDRSN3ozZm1rZkw4cF9sWnJReS1HNXNiWjVMNkxLRVNTVjNGUmZxTHVVaXl2MHRHOFlZbTJGV1c?oc=5", "tier": "direct", "title": "Travere Therapeutics (NASDAQ:TVTX) Passes Minervini Trend Template With High-Growth Momentum", "topics": [], "summary": "", "age_days": 3.6, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "79ec5638305d36c6a72ea0dc8b3470dbccf3714015dbb1b04d93def11c8d37ac", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOX29QeTAzZFFMZEw3U1MxZjdfU2NMNmJHSVBvTGNFRHVwVzhnZzdHUnFhazMtcHhWNUFHeUVTZE1xZWNsOHg3dnRmVmVQbWRYTEdjTndEUk11a2c5TzNkUWpidndWMWpueXJZdlp0Ml9sRHNxU2VkMzRfU01TWlBlbVJaR1JBc0E1eDBFaFcyLXZGQUNJbTVzZXJYd3hXZDd2SDRSN3ozZm1rZkw4cF9sWnJReS1HNXNiWjVMNkxLRVNTVjNGUmZxTHVVaXl2MHRHOFlZbTJGV1c?oc=5", "source_name": "ChartMill", "published_at": "2026-09-21T12:41:07+00:00", "source_names": ["ChartMill"], "target_scope": "Travere Therapeutics (NASDAQ:TVTX) Passes Minervini Trend Template With High-Growth Momentum", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 29.1, "sentiment_pct": 50, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.015552, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TVTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "21 Sep 2026 12:41", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TVTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.investing.com/news/insider-trading-news/travere-therapeutics-evp-peter-heerma-sells-178m-in-company-stock-93CH-4906654", "tier": "direct", "title": "Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Peter Heerma, EVP and CCO at Travere Therapeutics (NASDAQ:TVTX), sold approximately $17.86 million worth of company stock through a pre-arranged trading plan between September 15-17, 2026. Concurrently, he acquired about $4.05 million in common stock by exercising employee options. These transactions occurred as TVTX shares approached a 52-week high, with the stock deemed overvalued by InvestingPro analysis, despite the company reporting strong Q2 2026 revenue driven by its kidney drug, FILSPARI.", "age_days": 6.4, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "09b1f3ab1eb169a510d1af9da30e4e4cf6402930291b7dff08dfdf996a486157", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.investing.com/news/insider-trading-news/travere-therapeutics-evp-peter-heerma-sells-178m-in-company-stock-93CH-4906654", "source_name": "Investing.com", "published_at": "2026-09-18T15:53:12", "source_names": ["Investing.com"], "target_scope": "Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock Peter Heerma, EVP and CCO at Travere Therapeutics (NASDAQ:TVTX), sold approximately $17.86 million worth of company stock through a pre-arranged trading plan between September 15-17, 2026. These transactions occurred as TVTX shares approached a 52-week high, with the stock deemed overvalued by InvestingPro analysis, despite the company reporting strong Q2 2026 revenue driven by its kidney drug, FILSPARI.", "tone_signals": ["Operating growth", "Negative valuation view"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 41.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.077205, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.574, "provider_symbols": ["TVTX", "TVTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "18 Sep 2026 15:53", "direction_included": false, "sentiment_conflict": 0.27, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TVTX", "provider_directional_mass": 0.1128}, {"url": "https://www.marketscreener.com/news/travere-therapeutics-insider-sold-shares-worth-25-390-729-according-to-a-recent-sec-filing-ce785adad88af424", "tier": "direct", "title": "Travere Therapeutics Insider Sold Shares Worth $25,390,729, According to a Recent SEC Filing", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "An insider at Travere Therapeutics sold shares valued at $25,390,729, as reported in a recent SEC filing. The article, published on September 18, 2026, by MT Newswires, provides this specific transaction detail among other insider sales for the company. Travere Therapeutics is a biopharmaceutical firm focused on rare kidney and metabolic diseases.", "age_days": 6.4, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "negative", "story_key": "9cc40a268a4b614dea0ac77ae5a95b56273b2fd9cb7006f56b2f689717baf983", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.marketscreener.com/news/travere-therapeutics-insider-sold-shares-worth-25-390-729-according-to-a-recent-sec-filing-ce785adad88af424", "source_name": "www.marketscreener.com", "published_at": "2026-09-18T15:53:12", "source_names": ["www.marketscreener.com"], "target_scope": "Travere Therapeutics Insider Sold Shares Worth $25,390,729, According to a Recent SEC Filing An insider at Travere Therapeutics sold shares valued at $25,390,729, as reported in a recent SEC filing. Travere Therapeutics is a biopharmaceutical firm focused on rare kidney and metabolic diseases.", "tone_signals": ["Institutional or insider selling"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 41.0, "sentiment_pct": 40, "evidence_basis": "archived_article", "evidence_share": 21.1, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.08119, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.634, "provider_symbols": ["TVTX", "TVTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 46, "published_display": "18 Sep 2026 15:53", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "21.1", "target_provider_symbol": "TVTX", "provider_directional_mass": 0.3406}, {"url": "https://www.biospace.com/press-releases/travere-therapeutics-to-present-at-the-stifel-2026-virtual-immunology-and-inflammation-forum", "tier": "direct", "title": "Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum", "topics": ["Biotech", "Finance", "Life Sciences"], "summary": "Travere Therapeutics, Inc. (Nasdaq: TVTX) announced that its management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET. A live webcast of the presentation will be available on the Investor page of Travere\u2019s website, with a replay accessible for up to 30 days. The company, a biopharmaceutical firm focused on rare diseases, aims to develop and deliver life-changing therapies to patients and caregivers.", "age_days": 6.5, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "6624e3fdd06cfb21c65daf66d94f02accb3944376b13297691194b3e9f680d14", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.biospace.com/press-releases/travere-therapeutics-to-present-at-the-stifel-2026-virtual-immunology-and-inflammation-forum", "source_name": "BioSpace", "published_at": "2026-09-18T15:10:34", "source_names": ["BioSpace"], "target_scope": "Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum Travere Therapeutics, Inc. (Nasdaq: TVTX) announced that its management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. A live webcast of the presentation will be available on the Investor page of Travere\u2019s website, with a replay accessible for up to 30 days.", "tone_signals": [], "company_focus": 0.78, "cross_listing": false, "entity_mapped": true, "freshness_pct": 10.7, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.00437, "influence_label": "None", "provider_symbol": "TVTX.US", "relevance_score": 0.78, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["1963.HK", "SF", "SF.US", "TVTX", "TVTX.ARCHIVE", "TVTX.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 78, "evidence_strength": 0, "published_display": "18 Sep 2026 15:10", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Shared story", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TVTX", "provider_directional_mass": 0.0387}, {"url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNR2J5Q0FmYUM5cmEzLW4xSmh3aFVJckliQjVMZVJITE9XTy1jeC1pSkJyUUpfcWhMSWxsWkxxSy1GOGo0bmUxSmJKcWlpQjBsYXFJM21DZUZ4WWpEZVZ3alhCSEowODVKaHVBWTd0b3R6cldzYVBuQ1M5ZFlWbWlUWVJSM1AtdS1HTEt6bndfc0VDSFc3M1hkWWJQcm9CSVdyMlBfRGpjRWczRW11ckxEWWZqRE0wZXBsUE5Nd2xJSmd2MlFWTW9MSDN6MnFKY2x0ZHJHTVJfZlpuRFcxbE1XOHBJVXFvMXRBZV84?oc=5", "tier": "direct", "title": "TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside", "topics": [], "summary": "", "age_days": 12.3, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "057c66f6a2565465df2d00d2fc1789526f3710e2f55cbd49d0b76a13a1f935af", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNR2J5Q0FmYUM5cmEzLW4xSmh3aFVJckliQjVMZVJITE9XTy1jeC1pSkJyUUpfcWhMSWxsWkxxSy1GOGo0bmUxSmJKcWlpQjBsYXFJM21DZUZ4WWpEZVZ3alhCSEowODVKaHVBWTd0b3R6cldzYVBuQ1M5ZFlWbWlUWVJSM1AtdS1HTEt6bndfc0VDSFc3M1hkWWJQcm9CSVdyMlBfRGpjRWczRW11ckxEWWZqRE0wZXBsUE5Nd2xJSmd2MlFWTW9MSDN6MnFKY2x0ZHJHTVJfZlpuRFcxbE1XOHBJVXFvMXRBZV84?oc=5", "source_name": "Stocktwits", "published_at": "2026-09-12T19:17:30+00:00", "source_names": ["Stocktwits"], "target_scope": "TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside", "tone_signals": ["Negative market reaction"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 5.8, "sentiment_pct": 46, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.006034, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 53, "model_confidence": 0.567, "provider_symbols": ["TVTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "12 Sep 2026 19:17", "direction_included": false, "sentiment_conflict": 0.667, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TVTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://ca.finance.yahoo.com/news/travere-therapeutics-reports-inducement-grants-210000130.html", "tier": "direct", "title": "Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "topics": ["Biopharmaceuticals", "Equity Grants", "Finance", "Life Sciences", "Nasdaq"], "summary": "Travere Therapeutics announced that its Board of Directors' Compensation Committee granted inducement equity awards to 16 new employees. These grants, totaling 56,220 restricted stock units (RSUs), are an inducement for their employment under Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on continued employment.", "age_days": 13.4, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "41012b15a736b9ece5ffcc3c70b2fb044bc572acad481847dbf457dc996264d5", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://ca.finance.yahoo.com/news/travere-therapeutics-reports-inducement-grants-210000130.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-09-11T16:00:00", "source_names": ["Yahoo! Finance Canada"], "target_scope": "Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Travere Therapeutics announced that its Board of Directors' Compensation Committee granted inducement equity awards to 16 new employees.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 1.0, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.000595, "influence_label": "None", "provider_symbol": "TVTX.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TVTX", "TVTX.ARCHIVE", "TVTX.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Sep 2026 16:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TVTX", "provider_directional_mass": 0.1027}, {"url": "https://www.investing.com/news/company-news/travere-therapeutics-stock-hits-52week-high-at-6825-usd-93CH-4896415", "tier": "direct", "title": "Travere Therapeutics stock hits 52-week high at 68.25 USD", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Travere Therapeutics (TVTX) stock reached a new 52-week high of $68.25, marking a significant 172.32% increase over the past year due to strong investor confidence and 77% revenue growth. The company's kidney drug, FILSPARI, has been a key driver, with second-quarter revenue exceeding forecasts at $169.6 million. Despite appearing overvalued, analysts predict profitability for TVTX this year.", "age_days": 13.7, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "b59ecec7ef5744c3ac14a8b23f1896c3a035bfc47c852ebee8ecfcf5a6c8305f", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.investing.com/news/company-news/travere-therapeutics-stock-hits-52week-high-at-6825-usd-93CH-4896415", "source_name": "Investing.com", "published_at": "2026-09-11T08:57:54", "source_names": ["Investing.com"], "target_scope": "Travere Therapeutics stock hits 52-week high at 68.25 USD Travere Therapeutics (TVTX) stock reached a new 52-week high of $68.25, marking a significant 172.32% increase over the past year due to strong investor confidence and 77% revenue growth. Despite appearing overvalued, analysts predict profitability for TVTX this year.", "tone_signals": ["Operating growth", "Negative valuation view"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 14.9, "sentiment_pct": 53, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.03202, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.594, "provider_symbols": ["TVTX", "TVTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "11 Sep 2026 08:57", "direction_included": false, "sentiment_conflict": 0.27, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TVTX", "provider_directional_mass": 0.8913}, {"url": "https://www.mmm-online.com/news/fda-untitled-letter-travere-therapeutics-kidney-disease-drug-filspari", "tier": "direct", "title": "FDA issues Untitled Letter to Travere Therapeutics over visual aid for kidney disease drug Filspari", "topics": ["Finance", "Life Sciences"], "summary": "The FDA's Office of Prescription Drug Promotion has issued an Untitled Letter to Travere Therapeutics concerning its visual aid for the kidney disease drug, Filspari. The agency claims that several statements in the visual aid, intended for physicians, are misleading as they are not supported by clinical data. The FDA highlighted issues with claims regarding \"kidney preservation,\" \"complete remission of proteinuria,\" and the drug being \"well tolerated,\" demanding a response from Travere Therapeutics within 15 working days.", "age_days": 15.6, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "971593a78ca93d84089001377697503b9ca33ec1db56e376b92d7e8fb329f0f0", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.mmm-online.com/news/fda-untitled-letter-travere-therapeutics-kidney-disease-drug-filspari", "source_name": "Medical Marketing and Media", "published_at": "2026-09-09T11:02:34", "source_names": ["Medical Marketing and Media"], "target_scope": "FDA issues Untitled Letter to Travere Therapeutics over visual aid for kidney disease drug Filspari The FDA's Office of Prescription Drug Promotion has issued an Untitled Letter to Travere Therapeutics concerning its visual aid for the kidney disease drug, Filspari. The FDA highlighted issues with claims regarding \"kidney preservation,\" \"complete remission of proteinuria,\" and the drug being \"well tolerated,\" demanding a response from Travere Therapeutics within 15 working days.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.4, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 0.000277, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.4, "provider_symbols": ["TVTX", "TVTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "09 Sep 2026 11:02", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TVTX", "provider_directional_mass": 0.6489}, {"url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPb0EtcjFYdFRqd1VqXzh0bW56SEtPbk8xajRHbm95SU5SWmx0Zkd3bDFQc2U4a0hxaVVIcWtXbHVEcF9sU2RyWjlRcUhMVGpnbVN2ZHNvN25LM1BvNUN3anVHQVk1RzRlOGYydF9nQkFQcW5hX3pSdkVPR1M0YnBOVQ?oc=5", "tier": "direct", "title": "Travere Therapeutics' Outlook Brightens As Turnaround Looms", "topics": [], "summary": "Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers near a buy zone. Continue Reading", "age_days": 16.8, "is_stale": false, "provider": "google_news", "providers": ["google_news"], "sentiment": "neutral", "story_key": "92cc0f69f2d147f8e0f6af672c7047250e1e7d0e25576c869125c4c0ba5dc39c", "event_type": "guidance", "tier_label": "Direct company coverage", "event_label": "Guidance", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPb0EtcjFYdFRqd1VqXzh0bW56SEtPbk8xajRHbm95SU5SWmx0Zkd3bDFQc2U4a0hxaVVIcWtXbHVEcF9sU2RyWjlRcUhMVGpnbVN2ZHNvN25LM1BvNUN3anVHQVk1RzRlOGYydF9nQkFQcW5hX3pSdkVPR1M0YnBOVQ?oc=5", "source_name": "Investor's Business Daily", "published_at": "2026-09-08T07:00:00+00:00", "source_names": ["Investor's Business Daily"], "target_scope": "Travere Therapeutics' Outlook Brightens As Turnaround Looms Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers near a buy zone.", "tone_signals": [], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 18.9, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 2, "durable_archive": false, "evidence_weight": 0.021825, "influence_label": "None", "provider_symbol": "TVTX.US", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 53, "model_confidence": 0.4, "provider_symbols": ["TVTX", "TVTX.ARCHIVE", "TVTX.US"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "08 Sep 2026 07:00", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TVTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNR2J5Q0FmYUM5cmEzLW4xSmh3aFVJckliQjVMZVJITE9XTy1jeC1pSkJyUUpfcWhMSWxsWkxxSy1GOGo0bmUxSmJKcWlpQjBsYXFJM21DZUZ4WWpEZVZ3alhCSEowODVKaHVBWTd0b3R6cldzYVBuQ1M5ZFlWbWlUWVJSM1AtdS1HTEt6bndfc0VDSFc3M1hkWWJQcm9CSVdyMlBfRGpjRWczRW11ckxEWWZqRE0wZXBsUE5Nd2xJSmd2MlFWTW9MSDN6MnFKY2x0ZHJHTVJfZlpuRFcxbE1XOHBJVXFvMXRBZV84?oc=5", "tier": "direct", "title": "TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside", "topics": [], "summary": "", "age_days": 19.3, "is_stale": false, "provider": "archive", "providers": ["archive"], "sentiment": "neutral", "story_key": "057c66f6a2565465df2d00d2fc1789526f3710e2f55cbd49d0b76a13a1f935af", "event_type": "analyst", "tier_label": "Direct company coverage", "event_label": "Analyst action", "source_kind": "publisher", "source_link": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNR2J5Q0FmYUM5cmEzLW4xSmh3aFVJckliQjVMZVJITE9XTy1jeC1pSkJyUUpfcWhMSWxsWkxxSy1GOGo0bmUxSmJKcWlpQjBsYXFJM21DZUZ4WWpEZVZ3alhCSEowODVKaHVBWTd0b3R6cldzYVBuQ1M5ZFlWbWlUWVJSM1AtdS1HTEt6bndfc0VDSFc3M1hkWWJQcm9CSVdyMlBfRGpjRWczRW11ckxEWWZqRE0wZXBsUE5Nd2xJSmd2MlFWTW9MSDN6MnFKY2x0ZHJHTVJfZlpuRFcxbE1XOHBJVXFvMXRBZV84?oc=5", "source_name": "Stocktwits", "published_at": "2026-09-05T18:53:23+00:00", "source_names": ["Stocktwits"], "target_scope": "TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside", "tone_signals": ["Negative market reaction"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 1.2, "sentiment_pct": 46, "evidence_basis": "headline_only", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": true, "evidence_weight": 0.001193, "influence_label": "None", "provider_symbol": "", "relevance_score": 0.78, "archive_provider": "google_news", "event_confidence": 53, "model_confidence": 0.567, "provider_symbols": ["TVTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "05 Sep 2026 18:53", "direction_included": false, "sentiment_conflict": 0.667, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TVTX.ARCHIVE", "provider_directional_mass": null}, {"url": "https://www.investing.com/news/company-news/travere-therapeutics-stock-hits-52week-high-at-6797-usd-93CH-4888110", "tier": "direct", "title": "Travere Therapeutics stock hits 52-week high at 67.97 USD", "topics": ["Earnings", "Financial Markets", "Life Sciences"], "summary": "Travere Therapeutics (TVTX) stock recently hit a 52-week high of $68.03, reflecting a 243% 1-year return, driven by strong investor confidence and impressive Q2 revenue of $169.6 million. This performance was significantly boosted by high demand for its kidney drug, FILSPARI, leading Stifel to raise its price target to $62. The stock is currently trading above its Fair Value according to InvestingPro data, signaling strong future growth expectations.", "age_days": 20.9, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "positive", "story_key": "12d7f16e7eff2878b085881bf6b4e76a952d83e4afa152df5ff6407888d77593", "event_type": "earnings", "tier_label": "Direct company coverage", "event_label": "Earnings", "source_kind": "publisher", "source_link": "https://www.investing.com/news/company-news/travere-therapeutics-stock-hits-52week-high-at-6797-usd-93CH-4888110", "source_name": "Investing.com", "published_at": "2026-09-04T04:54:55", "source_names": ["Investing.com"], "target_scope": "Travere Therapeutics stock hits 52-week high at 67.97 USD Travere Therapeutics (TVTX) stock recently hit a 52-week high of $68.03, reflecting a 243% 1-year return, driven by strong investor confidence and impressive Q2 revenue of $169.6 million.", "tone_signals": ["Analyst upgrade", "Operating growth"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 5.5, "sentiment_pct": 63, "evidence_basis": "archived_article", "evidence_share": 4.3, "score_included": true, "duplicate_count": 4, "durable_archive": false, "evidence_weight": 0.016461, "influence_label": "Medium", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 61, "model_confidence": 0.656, "provider_symbols": ["TVTX", "TVTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 40, "published_display": "04 Sep 2026 04:54", "direction_included": true, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "4.3", "target_provider_symbol": "TVTX", "provider_directional_mass": 0.8194}, {"url": "https://kalkinemedia.com/us/news/announcements/travere-therapeutics-cfo-christopher-r-cline-executes-642-share-sale-for-tax-withholding-on-rsu-vesting", "tier": "direct", "title": "Travere Therapeutics CFO Christopher R. Cline Executes 642-Share Sale for Tax Withholding on RSU Vesting", "topics": ["Finance", "Life Sciences"], "summary": "Christopher R. Cline, CFO of Travere Therapeutics, sold 642 shares of common stock on September 2, 2026, at $66.37 per share. This transaction was not a discretionary trade but a mandatory \"sell to cover\" to fulfill tax withholding obligations arising from vested restricted stock units. Following the sale, Cline beneficially owns 118,016 shares of the company's common stock.", "age_days": 21.0, "is_stale": false, "provider": "alphavantage", "providers": ["alphavantage"], "sentiment": "neutral", "story_key": "187eef99980eb23d746b303b330ccb0e909716241b65d83d72007cba59d088de", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://kalkinemedia.com/us/news/announcements/travere-therapeutics-cfo-christopher-r-cline-executes-642-share-sale-for-tax-withholding-on-rsu-vesting", "source_name": "Kalkine Media", "published_at": "2026-09-04T02:31:14", "source_names": ["Kalkine Media"], "target_scope": "Travere Therapeutics CFO Christopher R. Cline, CFO of Travere Therapeutics, sold 642 shares of common stock on September 2, 2026, at $66.37 per share.", "tone_signals": ["Institutional or insider selling"], "company_focus": 1.0, "cross_listing": false, "entity_mapped": true, "freshness_pct": 0.1, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "durable_archive": false, "evidence_weight": 5.7e-05, "influence_label": "None", "provider_symbol": "", "relevance_score": 1.0, "archive_provider": "", "event_confidence": 35, "model_confidence": 0.526, "provider_symbols": ["TVTX", "TVTX.ARCHIVE"], "sentiment_origin": "stored_reclassified", "company_focus_pct": 100, "evidence_strength": 0, "published_display": "04 Sep 2026 02:31", "direction_included": false, "sentiment_conflict": 0.0, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0", "target_provider_symbol": "TVTX", "provider_directional_mass": 0.0423}], "industry": [], "sector": []}, "detail_intelligence": {"headline": "Early balanced news score", "summary": "21 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.", "status": "provisional", "metrics": [{"label": "News score", "value": 49, "display": "49", "tone": "neutral", "note": "Early balanced news score"}, {"label": "Confidence", "value": 30, "display": "30", "tone": "negative", "note": "thin evidence"}, {"label": "Company news", "value": 95, "display": "95%", "tone": "positive", "note": "21 company stories"}, {"label": "Story agreement", "value": 91, "display": "91", "tone": "positive", "note": "9/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 8, "note": "0.384 after freshness weighting"}, {"label": "Source breadth", "value": 80, "note": "4 independent publishers"}, {"label": "Company relevance", "value": 95, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 37, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 91, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 74, "note": "less reliance on one publisher"}], "freshness": 37, "source_independence": 74, "timeline": [{"date": "2026-08-29", "label": "29 Aug", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-30", "label": "30 Aug", "count": 0, "score": null, "tone": "neutral", "x": 73.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-31", "label": "31 Aug", "count": 0, "score": null, "tone": "neutral", "x": 105.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-01", "label": "01 Sep", "count": 0, "score": null, "tone": "neutral", "x": 136.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-02", "label": "02 Sep", "count": 0, "score": null, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-03", "label": "03 Sep", "count": 0, "score": null, "tone": "neutral", "x": 199.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-04", "label": "04 Sep", "count": 2, "score": 63, "tone": "positive", "x": 231.5, "y": 111.3, "volume_height": 20.8, "volume_y": 245.2}, {"date": "2026-09-05", "label": "05 Sep", "count": 1, "score": 46, "tone": "neutral", "x": 263.1, "y": 142.3, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-09-06", "label": "06 Sep", "count": 0, "score": null, "tone": "neutral", "x": 294.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-07", "label": "07 Sep", "count": 0, "score": null, "tone": "neutral", "x": 326.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-08", "label": "08 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-09-09", "label": "09 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 389.4, "y": 135.0, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-09-10", "label": "10 Sep", "count": 0, "score": null, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-11", "label": "11 Sep", "count": 2, "score": 53, "tone": "neutral", "x": 452.6, "y": 129.5, "volume_height": 20.8, "volume_y": 245.2}, {"date": "2026-09-12", "label": "12 Sep", "count": 1, "score": 46, "tone": "neutral", "x": 484.2, "y": 142.3, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-09-13", "label": "13 Sep", "count": 0, "score": null, "tone": "neutral", "x": 515.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-14", "label": "14 Sep", "count": 0, "score": null, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-15", "label": "15 Sep", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-16", "label": "16 Sep", "count": 0, "score": null, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-17", "label": "17 Sep", "count": 0, "score": null, "tone": "neutral", "x": 642.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-18", "label": "18 Sep", "count": 3, "score": 45, "tone": "neutral", "x": 673.7, "y": 144.1, "volume_height": 31.2, "volume_y": 234.8}, {"date": "2026-09-19", "label": "19 Sep", "count": 0, "score": null, "tone": "neutral", "x": 705.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-20", "label": "20 Sep", "count": 0, "score": null, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-21", "label": "21 Sep", "count": 2, "score": 50, "tone": "neutral", "x": 768.5, "y": 135.0, "volume_height": 20.8, "volume_y": 245.2}, {"date": "2026-09-22", "label": "22 Sep", "count": 5, "score": 46, "tone": "neutral", "x": 800.1, "y": 142.3, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-09-23", "label": "23 Sep", "count": 3, "score": 50, "tone": "neutral", "x": 831.7, "y": 135.0, "volume_height": 31.2, "volume_y": 234.8}, {"date": "2026-09-24", "label": "24 Sep", "count": 0, "score": null, "tone": "neutral", "x": 863.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-25", "label": "25 Sep", "count": 0, "score": null, "tone": "neutral", "x": 894.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-26", "label": "26 Sep", "count": 0, "score": null, "tone": "neutral", "x": 926.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-27", "label": "27 Sep", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "231.5,111.3 263.1,142.3 357.9,135.0 389.4,135.0 452.6,129.5 484.2,142.3 673.7,144.1 768.5,135.0 800.1,142.3 831.7,135.0", "timeline_has_signal": true, "timeline_start": "29 Aug", "timeline_mid": "13 Sep", "timeline_end": "27 Sep", "momentum": {"label": "Cooling", "tone": "neutral", "recent_score": null, "prior_score": 47, "delta": null, "recent_count": 0, "prior_count": 10, "volume_delta": -10, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "early_change": {"label": "No new story in 24 hours", "tone": "neutral", "latest_score": null, "baseline_score": 47, "delta": null, "latest_count": 0, "baseline_count": 10, "confirmed": false, "note": "A comparison needs current and earlier-week company news"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 0, "share": 0}, {"label": "1 to 3 days", "count": 0, "share": 0}, {"label": "4 to 7 days", "count": 10, "share": 48}, {"label": "8 to 14 days", "count": 3, "share": 14}, {"label": "15 to 21 days", "count": 5, "share": 24}, {"label": "22 to 30 days", "count": 3, "share": 14}], "source_profile": [{"label": "Investing.com", "count": 5, "share": 24, "score": 48, "tone": "neutral"}, {"label": "BioSpace", "count": 3, "share": 14, "score": 50, "tone": "neutral"}, {"label": "Stocktwits", "count": 2, "share": 10, "score": 46, "tone": "neutral"}, {"label": "www.marketscreener.com", "count": 1, "share": 5, "score": 40, "tone": "negative"}, {"label": "Market source", "count": 1, "share": 5, "score": 41, "tone": "negative"}, {"label": "Contract Pharma", "count": 1, "share": 5, "score": 58, "tone": "positive"}, {"label": "finance.yahoo.com", "count": 1, "share": 5, "score": 50, "tone": "neutral"}], "event_profile": [{"label": "Market update", "count": 12, "share": 57, "score": 47, "tone": "neutral"}, {"label": "Earnings", "count": 6, "share": 29, "score": 48, "tone": "neutral"}, {"label": "Analyst action", "count": 2, "share": 10, "score": 46, "tone": "neutral"}, {"label": "Guidance", "count": 1, "share": 5, "score": 50, "tone": "neutral"}], "topics": [{"label": "Life Sciences", "count": 16, "share": 76}, {"label": "Financial Markets", "count": 7, "share": 33}, {"label": "Finance", "count": 6, "share": 29}, {"label": "Earnings", "count": 6, "share": 29}, {"label": "Biotech", "count": 3, "share": 14}, {"label": "Revenue", "count": 1, "share": 5}, {"label": "Rare Diseases", "count": 1, "share": 5}, {"label": "Price To Sales", "count": 1, "share": 5}, {"label": "Nasdaq", "count": 1, "share": 5}, {"label": "Leadership Change", "count": 1, "share": 5}], "supporting": [{"label": "Direct evidence", "text": "21 current stories are mapped specifically to TVTX."}, {"label": "Source breadth", "text": "The score uses 4 publishers rather than depending on one outlet."}], "tempering": [{"label": "Too little evidence", "text": "The stories agree, but freshness-weighted evidence is only 0.384."}, {"label": "Confidence", "text": "Confidence is 30/100, below the threshold for a firm score."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"url": "https://www.investing.com/news/company-news/travere-receives-patent-allowance-for-filspari-use-in-fsgs-93CH-4912662", "tier": "direct", "title": "Travere receives patent allowance for FILSPARI use in FSGS", "topics": ["Life Sciences"], "summary": "Travere Therapeutics Inc. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering certain methods of using its drug FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS). This patent is expected to provide U.S. coverage for FILSPARI in FSGS until October 2037. The company plans to list the patent in the FDA's Orange Book, further securing its intellectual property for the rare disease treatment.", "age_days": 1.6, "is_stale": false, "sentiment": "neutral", "event_type": "general", "tier_label": "Direct company coverage", "event_label": "Market update", "source_kind": "publisher", "source_link": "https://www.investing.com/news/company-news/travere-receives-patent-allowance-for-filspari-use-in-fsgs-93CH-4912662", "source_name": "Investing.com", "published_at": "2026-09-23T11:51:32", "tone_signals": [], "company_focus": 1.0, "freshness_pct": 57.5, "sentiment_pct": 50, "evidence_basis": "archived_article", "evidence_share": 0.0, "score_included": true, "duplicate_count": 1, "evidence_weight": 0.049012, "influence_label": "None", "event_confidence": 35, "company_focus_pct": 100, "evidence_strength": 0, "published_display": "23 Sep 2026 11:51", "direction_included": false, "company_focus_label": "Main company", "source_link_is_lookup": false, "evidence_share_display": "0"}, "article_count": 21, "updated_at": "2026-09-25T02:12:50.233750+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 198.3, "label": "03 Apr 2026", "close": 30.44, "index": 100.0}, {"x": 78.4, "y": 204.2, "label": "10 Apr 2026", "close": 28.96, "index": 95.1}, {"x": 114.9, "y": 157.1, "label": "17 Apr 2026", "close": 40.77, "index": 133.9}, {"x": 151.3, "y": 158.2, "label": "24 Apr 2026", "close": 40.5, "index": 133.0}, {"x": 187.7, "y": 143.7, "label": "01 May 2026", "close": 44.12, "index": 144.9}, {"x": 224.2, "y": 149.8, "label": "08 May 2026", "close": 42.6, "index": 139.9}, {"x": 260.6, "y": 149.8, "label": "15 May 2026", "close": 42.59, "index": 139.9}, {"x": 297.0, "y": 142.5, "label": "22 May 2026", "close": 44.43, "index": 146.0}, {"x": 333.5, "y": 131.5, "label": "29 May 2026", "close": 47.18, "index": 155.0}, {"x": 369.9, "y": 137.0, "label": "05 Jun 2026", "close": 45.81, "index": 150.5}, {"x": 406.3, "y": 112.2, "label": "12 Jun 2026", "close": 52.04, "index": 171.0}, {"x": 442.8, "y": 99.8, "label": "19 Jun 2026", "close": 55.15, "index": 181.2}, {"x": 479.2, "y": 85.0, "label": "26 Jun 2026", "close": 58.85, "index": 193.3}, {"x": 515.6, "y": 92.7, "label": "03 Jul 2026", "close": 56.92, "index": 187.0}, {"x": 552.0, "y": 94.0, "label": "10 Jul 2026", "close": 56.59, "index": 185.9}, {"x": 588.5, "y": 93.5, "label": "17 Jul 2026", "close": 56.71, "index": 186.3}, {"x": 624.9, "y": 90.9, "label": "24 Jul 2026", "close": 57.36, "index": 188.4}, {"x": 661.3, "y": 96.8, "label": "31 Jul 2026", "close": 55.89, "index": 183.6}, {"x": 697.8, "y": 75.1, "label": "07 Aug 2026", "close": 61.32, "index": 201.4}, {"x": 734.2, "y": 71.9, "label": "14 Aug 2026", "close": 62.14, "index": 204.1}, {"x": 770.6, "y": 57.6, "label": "21 Aug 2026", "close": 65.71, "index": 215.9}, {"x": 807.1, "y": 57.8, "label": "28 Aug 2026", "close": 65.67, "index": 215.7}, {"x": 843.5, "y": 59.4, "label": "04 Sep 2026", "close": 65.28, "index": 214.5}, {"x": 879.9, "y": 55.8, "label": "11 Sep 2026", "close": 66.17, "index": 217.4}, {"x": 916.4, "y": 69.4, "label": "18 Sep 2026", "close": 62.76, "index": 206.2}, {"x": 952.8, "y": 82.6, "label": "25 Sep 2026", "close": 59.44, "index": 195.3}], "sentiment_points": [{"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 52, "tone": "neutral", "raw_score": 63, "confidence": 29, "stories": 5, "close": 58.85, "price_change": 6.7, "x": 484.4, "y": 126.3, "show_label": true, "label_y": 116.3}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 51, "tone": "neutral", "raw_score": 63, "confidence": 17, "stories": 10, "close": 56.92, "price_change": -3.3, "x": 520.8, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 52, "tone": "neutral", "raw_score": 67, "confidence": 29, "stories": 13, "close": 56.59, "price_change": -0.6, "x": 557.2, "y": 126.3, "show_label": true, "label_y": 116.3}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 51, "tone": "neutral", "raw_score": 62, "confidence": 26, "stories": 17, "close": 56.71, "price_change": 0.2, "x": 593.7, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 55, "tone": "neutral", "raw_score": 66, "confidence": 32, "stories": 22, "close": 57.36, "price_change": 1.1, "x": 630.1, "y": 120.8, "show_label": true, "label_y": 110.8}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 49, "tone": "neutral", "raw_score": 45, "confidence": 28, "stories": 29, "close": 55.89, "price_change": -2.6, "x": 666.5, "y": 131.8, "show_label": false, "label_y": 121.80000000000001}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 61, "tone": "positive", "raw_score": 68, "confidence": 43, "stories": 55, "close": 61.32, "price_change": 9.7, "x": 703.0, "y": 109.8, "show_label": true, "label_y": 99.8}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "label": "14 Aug 2026", "score": 58, "tone": "positive", "raw_score": 66, "confidence": 38, "stories": 64, "close": 62.14, "price_change": 1.3, "x": 739.4, "y": 115.3, "show_label": false, "label_y": 105.3}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "label": "21 Aug 2026", "score": 58, "tone": "positive", "raw_score": 66, "confidence": 37, "stories": 68, "close": 65.71, "price_change": 5.7, "x": 775.8, "y": 115.3, "show_label": true, "label_y": 105.3}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "label": "28 Aug 2026", "score": 54, "tone": "neutral", "raw_score": 66, "confidence": 25, "stories": 55, "close": 65.67, "price_change": -0.1, "x": 812.3, "y": 122.6, "show_label": false, "label_y": 112.6}, {"at": "2026-09-04T23:59:59.999Z", "date": "2026-09-04", "label": "04 Sep 2026", "score": 53, "tone": "neutral", "raw_score": 63, "confidence": 30, "stories": 36, "close": 65.28, "price_change": -0.6, "x": 848.7, "y": 124.5, "show_label": true, "label_y": 114.5}, {"at": "2026-09-11T23:59:59.999Z", "date": "2026-09-11", "label": "11 Sep 2026", "score": 51, "tone": "neutral", "raw_score": 63, "confidence": 21, "stories": 24, "close": 66.17, "price_change": 1.4, "x": 885.1, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-09-18T23:59:59.999Z", "date": "2026-09-18", "label": "18 Sep 2026", "score": 50, "tone": "neutral", "raw_score": 48, "confidence": 26, "stories": 18, "close": 62.76, "price_change": -5.2, "x": 921.6, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-09-25T23:59:59.999Z", "date": "2026-09-25", "label": "25 Sep 2026", "score": 49, "tone": "neutral", "raw_score": 45, "confidence": 31, "stories": 21, "close": 59.44, "price_change": -5.3, "x": 958.0, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}], "price_path": "42.0,198.3 78.4,204.2 114.9,157.1 151.3,158.2 187.7,143.7 224.2,149.8 260.6,149.8 297.0,142.5 333.5,131.5 369.9,137.0 406.3,112.2 442.8,99.8 479.2,85.0 515.6,92.7 552.0,94.0 588.5,93.5 624.9,90.9 661.3,96.8 697.8,75.1 734.2,71.9 770.6,57.6 807.1,57.8 843.5,59.4 879.9,55.8 916.4,69.4 952.8,82.6", "sentiment_path": "484.4,126.3 520.8,128.2 557.2,126.3 593.7,128.2 630.1,120.8 666.5,131.8 703.0,109.8 739.4,115.3 775.8,115.3 812.3,122.6 848.7,124.5 885.1,128.2 921.6,130.0 958.0,131.8", "score_version": "evidence-v10", "price_change": 95.3, "sentiment_change": -3, "recent_pairs": [{"at": "2026-09-25T23:59:59.999Z", "date": "2026-09-25", "label": "25 Sep 2026", "score": 49, "tone": "neutral", "raw_score": 45, "confidence": 31, "stories": 21, "close": 59.44, "price_change": -5.3, "x": 958.0, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}, {"at": "2026-09-18T23:59:59.999Z", "date": "2026-09-18", "label": "18 Sep 2026", "score": 50, "tone": "neutral", "raw_score": 48, "confidence": 26, "stories": 18, "close": 62.76, "price_change": -5.2, "x": 921.6, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-09-11T23:59:59.999Z", "date": "2026-09-11", "label": "11 Sep 2026", "score": 51, "tone": "neutral", "raw_score": 63, "confidence": 21, "stories": 24, "close": 66.17, "price_change": 1.4, "x": 885.1, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-09-04T23:59:59.999Z", "date": "2026-09-04", "label": "04 Sep 2026", "score": 53, "tone": "neutral", "raw_score": 63, "confidence": 30, "stories": 36, "close": 65.28, "price_change": -0.6, "x": 848.7, "y": 124.5, "show_label": true, "label_y": 114.5}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "label": "28 Aug 2026", "score": 54, "tone": "neutral", "raw_score": 66, "confidence": 25, "stories": 55, "close": 65.67, "price_change": -0.1, "x": 812.3, "y": 122.6, "show_label": false, "label_y": 112.6}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "label": "21 Aug 2026", "score": 58, "tone": "positive", "raw_score": 66, "confidence": 37, "stories": 68, "close": 65.71, "price_change": 5.7, "x": 775.8, "y": 115.3, "show_label": true, "label_y": 105.3}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "label": "14 Aug 2026", "score": 58, "tone": "positive", "raw_score": 66, "confidence": 38, "stories": 64, "close": 62.14, "price_change": 1.3, "x": 739.4, "y": 115.3, "show_label": false, "label_y": 105.3}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 61, "tone": "positive", "raw_score": 68, "confidence": 43, "stories": 55, "close": 61.32, "price_change": 9.7, "x": 703.0, "y": 109.8, "show_label": true, "label_y": 99.8}], "reconstructed": true, "latest_close": 59.44, "price_observations": 26, "sentiment_observations": 14, "sentiment_start_label": "26 Jun 2026", "sentiment_end_label": "25 Sep 2026", "sentiment_history_limited": false, "price_axis_high": 232.0, "price_axis_mid": 156.3, "price_axis_low": 80.5, "start_label": "03 Apr", "mid_label": "30 Jun", "end_label": "25 Sep", "live_score_version": "evidence-v10", "comparable_to_live": true}, "sentiment_history": [{"label": "23 Jun 23:59", "short_label": "23 Jun", "collected_at": "2026-06-23T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 3, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "25 Jun 23:59", "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 1, "score_change_display": "+1", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 4, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "26 Jun 23:59", "short_label": "26 Jun", "collected_at": "2026-06-26T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "27 Jun 23:59", "short_label": "27 Jun", "collected_at": "2026-06-27T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "28 Jun 23:59", "short_label": "28 Jun", "collected_at": "2026-06-28T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "29 Jun 23:59", "short_label": "29 Jun", "collected_at": "2026-06-29T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 8, "confidence": 22, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "30 Jun 23:59", "short_label": "30 Jun", "collected_at": "2026-06-30T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 9, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "03 Jul 23:59", "short_label": "03 Jul", "collected_at": "2026-07-03T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 10, "confidence": 17, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "04 Jul 23:59", "short_label": "04 Jul", "collected_at": "2026-07-04T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 11, "confidence": 17, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "09 Jul 23:59", "short_label": "09 Jul", "collected_at": "2026-07-09T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 2, "score_change_display": "+2", "confidence_change": 13, "article_change": 2, "tone": "neutral", "height": 4, "articles": 13, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "12 Jul 23:59", "short_label": "12 Jul", "collected_at": "2026-07-12T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 14, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "17 Jul 23:59", "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 3, "tone": "neutral", "height": 4, "articles": 17, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "19 Jul 23:59", "short_label": "19 Jul", "collected_at": "2026-07-19T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 18, "confidence": 21, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "20 Jul 23:59", "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 19, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "22 Jul 23:59", "short_label": "22 Jul", "collected_at": "2026-07-22T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 19, "confidence": 19, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 56, "delta": 6, "score_change": 5, "score_change_display": "+5", "confidence_change": 16, "article_change": 3, "tone": "neutral", "height": 12, "articles": 22, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "25 Jul 23:59", "short_label": "25 Jul", "collected_at": "2026-07-25T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -2, "score_change_display": "-2", "confidence_change": -5, "article_change": 0, "tone": "neutral", "height": 8, "articles": 22, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -4, "score_change_display": "-4", "confidence_change": 3, "article_change": 0, "tone": "neutral", "height": 4, "articles": 22, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "28 Jul 23:59", "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": 1, "article_change": 6, "tone": "neutral", "height": 4, "articles": 28, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 4, "articles": 28, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 29, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "01 Aug 23:59", "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 30, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 30, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "03 Aug 23:59", "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 30, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "04 Aug 23:59", "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 6, "score_change_display": "+6", "confidence_change": 9, "article_change": 7, "tone": "neutral", "height": 10, "articles": 37, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 63, "delta": 13, "score_change": 8, "score_change_display": "+8", "confidence_change": 16, "article_change": 9, "tone": "positive", "height": 26, "articles": 46, "confidence": 50, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "06 Aug 23:59", "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score": 62, "delta": 12, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": 5, "tone": "positive", "height": 24, "articles": 51, "confidence": 46, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 61, "delta": 11, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 4, "tone": "positive", "height": 22, "articles": 55, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 0, "tone": "positive", "height": 20, "articles": 55, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": -2, "score_change_display": "-2", "confidence_change": -6, "article_change": 0, "tone": "positive", "height": 16, "articles": 55, "confidence": 34, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 5, "tone": "neutral", "height": 14, "articles": 60, "confidence": 34, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "13 Aug 23:59", "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score": 59, "delta": 9, "score_change": 2, "score_change_display": "+2", "confidence_change": 2, "article_change": 1, "tone": "positive", "height": 18, "articles": 61, "confidence": 36, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "14 Aug 23:59", "short_label": "14 Aug", "collected_at": "2026-08-14T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": -1, "score_change_display": "-1", "confidence_change": 2, "article_change": 3, "tone": "positive", "height": 16, "articles": 64, "confidence": 38, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "16 Aug 23:59", "short_label": "16 Aug", "collected_at": "2026-08-16T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": -1, "score_change_display": "-1", "confidence_change": -6, "article_change": -2, "tone": "neutral", "height": 14, "articles": 62, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "17 Aug 23:59", "short_label": "17 Aug", "collected_at": "2026-08-17T23:59:59.999999+00:00", "score": 56, "delta": 6, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": 2, "tone": "neutral", "height": 12, "articles": 64, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "18 Aug 23:59", "short_label": "18 Aug", "collected_at": "2026-08-18T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 0, "tone": "neutral", "height": 14, "articles": 64, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "19 Aug 23:59", "short_label": "19 Aug", "collected_at": "2026-08-19T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": -2, "score_change_display": "-2", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 10, "articles": 64, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "20 Aug 23:59", "short_label": "20 Aug", "collected_at": "2026-08-20T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 2, "score_change_display": "+2", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 14, "articles": 65, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "21 Aug 23:59", "short_label": "21 Aug", "collected_at": "2026-08-21T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": 1, "score_change_display": "+1", "confidence_change": 5, "article_change": 3, "tone": "positive", "height": 16, "articles": 68, "confidence": 37, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "22 Aug 23:59", "short_label": "22 Aug", "collected_at": "2026-08-22T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": -3, "tone": "neutral", "height": 14, "articles": 65, "confidence": 36, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true}, {"label": "23 Aug 23:59", "short_label": "23 Aug", "collected_at": "2026-08-23T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 14, "articles": 66, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "04 Sep 23:59", "short_label": "04 Sep", "collected_at": "2026-09-04T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": -4, "score_change_display": "-4", "confidence_change": -4, "article_change": -30, "tone": "neutral", "height": 6, "articles": 36, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "05 Sep 23:59", "short_label": "05 Sep", "collected_at": "2026-09-05T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": -4, "tone": "neutral", "height": 6, "articles": 32, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "08 Sep 23:59", "short_label": "08 Sep", "collected_at": "2026-09-08T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": -5, "tone": "neutral", "height": 4, "articles": 27, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "09 Sep 23:59", "short_label": "09 Sep", "collected_at": "2026-09-09T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 28, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "11 Sep 23:59", "short_label": "11 Sep", "collected_at": "2026-09-11T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": -4, "tone": "neutral", "height": 4, "articles": 24, "confidence": 21, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "12 Sep 23:59", "short_label": "12 Sep", "collected_at": "2026-09-12T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 24, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "18 Sep 23:59", "short_label": "18 Sep", "collected_at": "2026-09-18T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": 6, "article_change": -6, "tone": "neutral", "height": 4, "articles": 18, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "21 Sep 23:59", "short_label": "21 Sep", "collected_at": "2026-09-21T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -7, "article_change": -4, "tone": "neutral", "height": 4, "articles": 14, "confidence": 19, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "22 Sep 23:59", "short_label": "22 Sep", "collected_at": "2026-09-22T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -2, "score_change_display": "-2", "confidence_change": 18, "article_change": 4, "tone": "neutral", "height": 4, "articles": 18, "confidence": 37, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "23 Sep 23:59", "short_label": "23 Sep", "collected_at": "2026-09-23T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 3, "tone": "neutral", "height": 4, "articles": 21, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "27 Sep 02:17", "short_label": "27 Sep", "collected_at": "2026-09-27T02:17:23.021736+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": -5, "article_change": 0, "tone": "neutral", "height": 4, "articles": 21, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v10", "live_version": "evidence-v10", "comparable_to_live": true, "reconstructed": true, "observations": 52, "span_label": "95 days", "first_score": 50, "latest_score": 49, "net_change": -1, "net_change_display": "-1", "direction": "Broadly stable", "high_score": 63, "low_score": 48, "latest_confidence": 30, "confidence_change": 5, "latest_articles": 21, "article_change": 18, "latest_label": "27 Sep 02:17", "latest_evidence_label": "Provisional", "chart_rows": [{"label": "23 Jun 23:59", "short_label": "23 Jun", "collected_at": "2026-06-23T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 3, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 42.0, "y": 135.0}, {"label": "25 Jun 23:59", "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 1, "score_change_display": "+1", "confidence_change": 3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 4, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 60.0, "y": 133.2}, {"label": "26 Jun 23:59", "short_label": "26 Jun", "collected_at": "2026-06-26T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 5, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 77.9, "y": 131.4}, {"label": "27 Jun 23:59", "short_label": "27 Jun", "collected_at": "2026-06-27T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 6, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 95.9, "y": 131.4}, {"label": "28 Jun 23:59", "short_label": "28 Jun", "collected_at": "2026-06-28T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 7, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 113.8, "y": 131.4}, {"label": "29 Jun 23:59", "short_label": "29 Jun", "collected_at": "2026-06-29T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 8, "confidence": 22, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 131.8, "y": 133.2}, {"label": "30 Jun 23:59", "short_label": "30 Jun", "collected_at": "2026-06-30T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 9, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 149.8, "y": 133.2}, {"label": "03 Jul 23:59", "short_label": "03 Jul", "collected_at": "2026-07-03T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 10, "confidence": 17, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 167.7, "y": 133.2}, {"label": "04 Jul 23:59", "short_label": "04 Jul", "collected_at": "2026-07-04T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 11, "confidence": 17, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 185.7, "y": 135.0}, {"label": "09 Jul 23:59", "short_label": "09 Jul", "collected_at": "2026-07-09T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 2, "score_change_display": "+2", "confidence_change": 13, "article_change": 2, "tone": "neutral", "height": 4, "articles": 13, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 203.6, "y": 131.4}, {"label": "12 Jul 23:59", "short_label": "12 Jul", "collected_at": "2026-07-12T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": 1, "tone": "neutral", "height": 4, "articles": 14, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 221.6, "y": 131.4}, {"label": "17 Jul 23:59", "short_label": "17 Jul", "collected_at": "2026-07-17T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 3, "tone": "neutral", "height": 4, "articles": 17, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 239.6, "y": 133.2}, {"label": "19 Jul 23:59", "short_label": "19 Jul", "collected_at": "2026-07-19T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 18, "confidence": 21, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 257.5, "y": 133.2}, {"label": "20 Jul 23:59", "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 19, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 275.5, "y": 133.2}, {"label": "22 Jul 23:59", "short_label": "22 Jul", "collected_at": "2026-07-22T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 19, "confidence": 19, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 293.5, "y": 133.2}, {"label": "23 Jul 23:59", "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score": 56, "delta": 6, "score_change": 5, "score_change_display": "+5", "confidence_change": 16, "article_change": 3, "tone": "neutral", "height": 12, "articles": 22, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 311.4, "y": 124.1}, {"label": "25 Jul 23:59", "short_label": "25 Jul", "collected_at": "2026-07-25T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": -2, "score_change_display": "-2", "confidence_change": -5, "article_change": 0, "tone": "neutral", "height": 8, "articles": 22, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 329.4, "y": 127.7}, {"label": "27 Jul 23:59", "short_label": "27 Jul", "collected_at": "2026-07-27T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -4, "score_change_display": "-4", "confidence_change": 3, "article_change": 0, "tone": "neutral", "height": 4, "articles": 22, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 347.3, "y": 135.0}, {"label": "28 Jul 23:59", "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -1, "score_change_display": "-1", "confidence_change": 1, "article_change": 6, "tone": "neutral", "height": 4, "articles": 28, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 365.3, "y": 136.8}, {"label": "29 Jul 23:59", "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 0, "tone": "neutral", "height": 4, "articles": 28, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 383.3, "y": 136.8}, {"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 29, "confidence": 29, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 401.2, "y": 136.8}, {"label": "01 Aug 23:59", "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 30, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 419.2, "y": 136.8}, {"label": "02 Aug 23:59", "short_label": "02 Aug", "collected_at": "2026-08-02T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 30, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 437.1, "y": 136.8}, {"label": "03 Aug 23:59", "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 30, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 455.1, "y": 136.8}, {"label": "04 Aug 23:59", "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": 6, "score_change_display": "+6", "confidence_change": 9, "article_change": 7, "tone": "neutral", "height": 10, "articles": 37, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 473.1, "y": 125.9}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 63, "delta": 13, "score_change": 8, "score_change_display": "+8", "confidence_change": 16, "article_change": 9, "tone": "positive", "height": 26, "articles": 46, "confidence": 50, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 491.0, "y": 111.3}, {"label": "06 Aug 23:59", "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score": 62, "delta": 12, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": 5, "tone": "positive", "height": 24, "articles": 51, "confidence": 46, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 509.0, "y": 113.2}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 61, "delta": 11, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 4, "tone": "positive", "height": 22, "articles": 55, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 526.9, "y": 115.0}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 60, "delta": 10, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": 0, "tone": "positive", "height": 20, "articles": 55, "confidence": 40, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 544.9, "y": 116.8}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": -2, "score_change_display": "-2", "confidence_change": -6, "article_change": 0, "tone": "positive", "height": 16, "articles": 55, "confidence": 34, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 562.9, "y": 120.4}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 5, "tone": "neutral", "height": 14, "articles": 60, "confidence": 34, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 580.8, "y": 122.3}, {"label": "13 Aug 23:59", "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score": 59, "delta": 9, "score_change": 2, "score_change_display": "+2", "confidence_change": 2, "article_change": 1, "tone": "positive", "height": 18, "articles": 61, "confidence": 36, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 598.8, "y": 118.6}, {"label": "14 Aug 23:59", "short_label": "14 Aug", "collected_at": "2026-08-14T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": -1, "score_change_display": "-1", "confidence_change": 2, "article_change": 3, "tone": "positive", "height": 16, "articles": 64, "confidence": 38, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 616.7, "y": 120.4}, {"label": "16 Aug 23:59", "short_label": "16 Aug", "collected_at": "2026-08-16T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": -1, "score_change_display": "-1", "confidence_change": -6, "article_change": -2, "tone": "neutral", "height": 14, "articles": 62, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 634.7, "y": 122.3}, {"label": "17 Aug 23:59", "short_label": "17 Aug", "collected_at": "2026-08-17T23:59:59.999999+00:00", "score": 56, "delta": 6, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": 2, "tone": "neutral", "height": 12, "articles": 64, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 652.7, "y": 124.1}, {"label": "18 Aug 23:59", "short_label": "18 Aug", "collected_at": "2026-08-18T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 1, "score_change_display": "+1", "confidence_change": 1, "article_change": 0, "tone": "neutral", "height": 14, "articles": 64, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 670.6, "y": 122.3}, {"label": "19 Aug 23:59", "short_label": "19 Aug", "collected_at": "2026-08-19T23:59:59.999999+00:00", "score": 55, "delta": 5, "score_change": -2, "score_change_display": "-2", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 10, "articles": 64, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 688.6, "y": 125.9}, {"label": "20 Aug 23:59", "short_label": "20 Aug", "collected_at": "2026-08-20T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 2, "score_change_display": "+2", "confidence_change": 1, "article_change": 1, "tone": "neutral", "height": 14, "articles": 65, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 706.5, "y": 122.3}, {"label": "21 Aug 23:59", "short_label": "21 Aug", "collected_at": "2026-08-21T23:59:59.999999+00:00", "score": 58, "delta": 8, "score_change": 1, "score_change_display": "+1", "confidence_change": 5, "article_change": 3, "tone": "positive", "height": 16, "articles": 68, "confidence": 37, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 724.5, "y": 120.4}, {"label": "22 Aug 23:59", "short_label": "22 Aug", "collected_at": "2026-08-22T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": -1, "score_change_display": "-1", "confidence_change": -1, "article_change": -3, "tone": "neutral", "height": 14, "articles": 65, "confidence": 36, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v10", "reconstructed": true, "x": 742.5, "y": 122.3}, {"label": "23 Aug 23:59", "short_label": "23 Aug", "collected_at": "2026-08-23T23:59:59.999999+00:00", "score": 57, "delta": 7, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 1, "tone": "neutral", "height": 14, "articles": 66, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 760.4, "y": 122.3}, {"label": "04 Sep 23:59", "short_label": "04 Sep", "collected_at": "2026-09-04T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": -4, "score_change_display": "-4", "confidence_change": -4, "article_change": -30, "tone": "neutral", "height": 6, "articles": 36, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 778.4, "y": 129.5}, {"label": "05 Sep 23:59", "short_label": "05 Sep", "collected_at": "2026-09-05T23:59:59.999999+00:00", "score": 53, "delta": 3, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": -4, "tone": "neutral", "height": 6, "articles": 32, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 796.4, "y": 129.5}, {"label": "08 Sep 23:59", "short_label": "08 Sep", "collected_at": "2026-09-08T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": -5, "tone": "neutral", "height": 4, "articles": 27, "confidence": 24, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 814.3, "y": 131.4}, {"label": "09 Sep 23:59", "short_label": "09 Sep", "collected_at": "2026-09-09T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 28, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 832.3, "y": 131.4}, {"label": "11 Sep 23:59", "short_label": "11 Sep", "collected_at": "2026-09-11T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": -4, "tone": "neutral", "height": 4, "articles": 24, "confidence": 21, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 850.2, "y": 133.2}, {"label": "12 Sep 23:59", "short_label": "12 Sep", "collected_at": "2026-09-12T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 24, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 868.2, "y": 133.2}, {"label": "18 Sep 23:59", "short_label": "18 Sep", "collected_at": "2026-09-18T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": 6, "article_change": -6, "tone": "neutral", "height": 4, "articles": 18, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 886.2, "y": 135.0}, {"label": "21 Sep 23:59", "short_label": "21 Sep", "collected_at": "2026-09-21T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -7, "article_change": -4, "tone": "neutral", "height": 4, "articles": 14, "confidence": 19, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 904.1, "y": 135.0}, {"label": "22 Sep 23:59", "short_label": "22 Sep", "collected_at": "2026-09-22T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -2, "score_change_display": "-2", "confidence_change": 18, "article_change": 4, "tone": "neutral", "height": 4, "articles": 18, "confidence": 37, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 922.1, "y": 138.6}, {"label": "23 Sep 23:59", "short_label": "23 Sep", "collected_at": "2026-09-23T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 3, "tone": "neutral", "height": 4, "articles": 21, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 940.0, "y": 138.6}, {"label": "27 Sep 02:17", "short_label": "27 Sep", "collected_at": "2026-09-27T02:17:23.021736+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": -5, "article_change": 0, "tone": "neutral", "height": 4, "articles": 21, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true, "x": 958.0, "y": 136.8}], "chart_points": "42.0,135.0 60.0,133.2 77.9,131.4 95.9,131.4 113.8,131.4 131.8,133.2 149.8,133.2 167.7,133.2 185.7,135.0 203.6,131.4 221.6,131.4 239.6,133.2 257.5,133.2 275.5,133.2 293.5,133.2 311.4,124.1 329.4,127.7 347.3,135.0 365.3,136.8 383.3,136.8 401.2,136.8 419.2,136.8 437.1,136.8 455.1,136.8 473.1,125.9 491.0,111.3 509.0,113.2 526.9,115.0 544.9,116.8 562.9,120.4 580.8,122.3 598.8,118.6 616.7,120.4 634.7,122.3 652.7,124.1 670.6,122.3 688.6,125.9 706.5,122.3 724.5,120.4 742.5,122.3 760.4,122.3 778.4,129.5 796.4,129.5 814.3,131.4 832.3,131.4 850.2,133.2 868.2,133.2 886.2,135.0 904.1,135.0 922.1,138.6 940.0,138.6 958.0,136.8", "changes": [{"label": "27 Sep 02:17", "short_label": "27 Sep", "collected_at": "2026-09-27T02:17:23.021736+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": -5, "article_change": 0, "tone": "neutral", "height": 4, "articles": 21, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "23 Sep 23:59", "short_label": "23 Sep", "collected_at": "2026-09-23T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 3, "tone": "neutral", "height": 4, "articles": 21, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "22 Sep 23:59", "short_label": "22 Sep", "collected_at": "2026-09-22T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -2, "score_change_display": "-2", "confidence_change": 18, "article_change": 4, "tone": "neutral", "height": 4, "articles": 18, "confidence": 37, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "21 Sep 23:59", "short_label": "21 Sep", "collected_at": "2026-09-21T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -7, "article_change": -4, "tone": "neutral", "height": 4, "articles": 14, "confidence": 19, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "18 Sep 23:59", "short_label": "18 Sep", "collected_at": "2026-09-18T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": 6, "article_change": -6, "tone": "neutral", "height": 4, "articles": 18, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "12 Sep 23:59", "short_label": "12 Sep", "collected_at": "2026-09-12T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 4, "articles": 24, "confidence": 20, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "11 Sep 23:59", "short_label": "11 Sep", "collected_at": "2026-09-11T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -2, "article_change": -4, "tone": "neutral", "height": 4, "articles": 24, "confidence": 21, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}, {"label": "09 Sep 23:59", "short_label": "09 Sep", "collected_at": "2026-09-09T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "neutral", "height": 4, "articles": 28, "confidence": 23, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v10", "reconstructed": true}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}